Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls
‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past...
Saved in:
Published in | Statistics in medicine Vol. 35; no. 3; pp. 325 - 347 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
10.02.2016
Wiley Subscription Services, Inc John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics: Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and – if not – discuss potential reasons why this did not happen. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. |
---|---|
AbstractList | ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie . The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics : Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and – if not – discuss potential reasons why this did not happen. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie . The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics : Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and – if not – discuss potential reasons why this did not happen. © 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. 'Multistage testing with adaptive designs' was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Köhne 1994 in Biometrics: Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and - if not - discuss potential reasons why this did not happen. 'Multistage testing with adaptive designs' was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in Medizin und Biologie. The journal does not exist anymore but the methodology found widespread interest in the scientific community over the past 25 years. The use of such multistage adaptive designs raised many controversial discussions from the beginning on, especially after the publication by Bauer and Kohne 1994 in Biometrics: Broad enthusiasm about potential applications of such designs faced critical positions regarding their statistical efficiency. Despite, or possibly because of, this controversy, the methodology and its areas of applications grew steadily over the years, with significant contributions from statisticians working in academia, industry and agencies around the world. In the meantime, such type of adaptive designs have become the subject of two major regulatory guidance documents in the US and Europe and the field is still evolving. Developments are particularly noteworthy in the most important applications of adaptive designs, including sample size reassessment, treatment selection procedures, and population enrichment designs. In this article, we summarize the developments over the past 25 years from different perspectives. We provide a historical overview of the early days, review the key methodological concepts and summarize regulatory and industry perspectives on such designs. Then, we illustrate the application of adaptive designs with three case studies, including unblinded sample size reassessment, adaptive treatment selection, and adaptive endpoint selection. We also discuss the availability of software for evaluating and performing such designs. We conclude with a critical review of how expectations from the beginning were fulfilled, and -- if not -- discuss potential reasons why this did not happen. |
Author | Dragalin, Vladimir König, Franz Bauer, Peter Wassmer, Gernot Bretz, Frank |
AuthorAffiliation | 6 Institute for Medical Statistics, Informatics and Epidemiology University of Cologne 50924 Köln Germany 3 Shanghai University of Finance and Economics China 4 Johnson and Johnson 1400 McKean Rd, Spring House PA 19477 U.S.A 1 Section of Medical Statistics Medical University of Vienna Spitalgasse 23 1090 Wien Austria 2 Novartis Pharma AG Lichtstrasse 35 4002 Basel Switzerland 5 Aptiv Solutions, an ICON plc company Robert‐Perthel‐Str. 77a 50739 Köln Germany |
AuthorAffiliation_xml | – name: 3 Shanghai University of Finance and Economics China – name: 1 Section of Medical Statistics Medical University of Vienna Spitalgasse 23 1090 Wien Austria – name: 6 Institute for Medical Statistics, Informatics and Epidemiology University of Cologne 50924 Köln Germany – name: 5 Aptiv Solutions, an ICON plc company Robert‐Perthel‐Str. 77a 50739 Köln Germany – name: 2 Novartis Pharma AG Lichtstrasse 35 4002 Basel Switzerland – name: 4 Johnson and Johnson 1400 McKean Rd, Spring House PA 19477 U.S.A |
Author_xml | – sequence: 1 givenname: Peter surname: Bauer fullname: Bauer, Peter organization: Section of Medical Statistics, Medical University of Vienna, Spitalgasse 23, 1090 Wien, Austria – sequence: 2 givenname: Frank surname: Bretz fullname: Bretz, Frank organization: Novartis Pharma AG, Lichtstrasse 35, 4002, Basel, Switzerland – sequence: 3 givenname: Vladimir surname: Dragalin fullname: Dragalin, Vladimir organization: Johnson and Johnson, 1400 McKean Rd, Spring House, PA, 19477, U.S.A – sequence: 4 givenname: Franz surname: König fullname: König, Franz organization: Section of Medical Statistics, Medical University of Vienna, Spitalgasse 23, 1090 Wien, Austria – sequence: 5 givenname: Gernot surname: Wassmer fullname: Wassmer, Gernot email: Correspondence to: Gernot Wassmer, Institute for Medical Statistics, Informatics and Epidemiology, University of Cologne 50924 Köln, Germany., gernot.wassmer@uni-koeln.de organization: Aptiv Solutions, an ICON plc company, Robert-Perthel-Str. 77a, 50739, Köln, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25778935$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUFP3DAQha2KqixQqb-gitRLL9l6nMST9FAJoZZSUZDKSpW4WI7jUNPETm0HyL8nK2ALqD3NYb55M2_eDtmyzmpC3gBdAqXsQzD9kufIXpAF0ApTyopyiywoQ0w5QrFNdkK4pBSgYPiKbLMCsayyYkFOVtfaxiltzZVOJi19SFybKGdb43sZnZ8S2cghrtuNDubCho-JGwbn42hNNDok0jbJYGIruy7skZdzDfr1fd0lZ18-rw6-psenh0cH-8ep4sBYWjKoZZXrTCNkWraSSdaoJi-Q14xlVEGLNaBqG6wVA97SSqEqcw0Ulcx2yac71WGse92o2YGXnRi86aWfhJNGPO1Y80tcuCvBeUmhglng_b2Ad39GHaLoTVC666TVbgwCkNOKZlVZzui7Z-ilG72dzc1UUQHPocpn6u3jizanPDz670blXQhetxsEqFhnKOYMxTrDGV0-Q5WJMhq39mK6fw2kdwPXptPTf4XF2dH3p7wJUd9seOl_C44ZFuLnyaFYfaPn-IOeC57dAoN8vWY |
CODEN | SMEDDA |
CitedBy_id | crossref_primary_10_1016_j_jclinepi_2018_02_013 crossref_primary_10_1097_PR9_0000000000000863 crossref_primary_10_1186_s12874_020_01169_7 crossref_primary_10_1016_j_cct_2017_04_005 crossref_primary_10_1186_s12916_020_01808_2 crossref_primary_10_1016_S2214_109X_20_30539_8 crossref_primary_10_1053_j_jvca_2018_02_009 crossref_primary_10_1016_j_jclinepi_2020_09_019 crossref_primary_10_1002_pst_2122 crossref_primary_10_1071_MA19004 crossref_primary_10_3389_fncel_2022_977679 crossref_primary_10_1016_S1441_2772_23_00939_0 crossref_primary_10_1002_sim_6797 crossref_primary_10_1002_pst_1951 crossref_primary_10_1002_sim_8291 crossref_primary_10_1177_1740774516689261 crossref_primary_10_1016_j_cct_2021_106397 crossref_primary_10_1186_s12874_024_02293_4 crossref_primary_10_1016_j_foodqual_2025_105523 crossref_primary_10_1016_j_jacbts_2019_02_005 crossref_primary_10_1080_19466315_2017_1422799 crossref_primary_10_1186_s13063_021_05130_x crossref_primary_10_1002_sim_7936 crossref_primary_10_1111_jcpt_12617 crossref_primary_10_1002_pst_2190 crossref_primary_10_1177_2168479017706526 crossref_primary_10_1186_s13023_018_0820_8 crossref_primary_10_1371_journal_pone_0231241 crossref_primary_10_1002_eat_24167 crossref_primary_10_1080_00031305_2021_1901782 crossref_primary_10_1002_pst_1942 crossref_primary_10_1016_j_softx_2023_101347 crossref_primary_10_1371_journal_pone_0269369 crossref_primary_10_1002_cpt_2575 crossref_primary_10_1002_pst_1926 crossref_primary_10_1002_sim_10310 crossref_primary_10_1038_s41393_020_00547_8 crossref_primary_10_1007_s40256_021_00480_y crossref_primary_10_1093_biostatistics_kxw012 crossref_primary_10_1002_sim_9288 crossref_primary_10_3390_stats4040062 crossref_primary_10_1136_bmj_m115 crossref_primary_10_1002_bimj_201900020 crossref_primary_10_1002_pst_2066 crossref_primary_10_1177_0962280219862313 crossref_primary_10_1186_s13063_023_07398_7 crossref_primary_10_1002_pst_2228 crossref_primary_10_1002_bimj_202100166 crossref_primary_10_1002_cpt_515 crossref_primary_10_1080_10543406_2020_1832110 crossref_primary_10_1002_ajp_23331 crossref_primary_10_1016_j_drudis_2017_10_012 crossref_primary_10_1177_2168479016667766 crossref_primary_10_1080_19466315_2018_1560359 crossref_primary_10_2196_medinform_8207 crossref_primary_10_1080_19466315_2022_2063171 crossref_primary_10_1016_j_cct_2024_107560 crossref_primary_10_1016_j_conctc_2023_101220 crossref_primary_10_1371_journal_pone_0163726 crossref_primary_10_1016_S1473_3099_24_00769_2 crossref_primary_10_1002_pst_1762 crossref_primary_10_1002_sim_9734 crossref_primary_10_1002_sim_9339 crossref_primary_10_1177_2168479019825634 crossref_primary_10_1177_2168479018807715 crossref_primary_10_1007_s43441_024_00676_9 crossref_primary_10_1214_20_AOS1978 crossref_primary_10_1093_biostatistics_kxac040 crossref_primary_10_1056_NEJMra1510061 crossref_primary_10_1080_17512433_2017_1321985 crossref_primary_10_1177_0962280217747312 crossref_primary_10_1186_s13063_015_1119_x crossref_primary_10_1002_sim_10130 crossref_primary_10_3390_s23020875 crossref_primary_10_1002_sim_8939 crossref_primary_10_1136_bmjopen_2022_069430 crossref_primary_10_1177_1740774517699406 crossref_primary_10_1016_j_cjca_2021_06_023 crossref_primary_10_1093_ecco_jcc_jjae026 crossref_primary_10_1002_pst_2168 crossref_primary_10_1080_19466315_2017_1323670 crossref_primary_10_1002_sim_7200 crossref_primary_10_1016_S2214_109X_20_30540_4 crossref_primary_10_1186_s12874_019_0800_2 crossref_primary_10_1177_0023677220907617 crossref_primary_10_1186_s13063_018_3012_x crossref_primary_10_1186_s12874_023_02024_1 crossref_primary_10_1002_pst_1753 crossref_primary_10_1002_pst_1873 crossref_primary_10_1080_19466315_2025_2455173 crossref_primary_10_1186_s40249_022_01031_6 crossref_primary_10_1093_cid_cix907 crossref_primary_10_1016_j_cct_2020_106215 crossref_primary_10_1186_s13063_019_3708_6 crossref_primary_10_1016_j_critrevonc_2024_104402 crossref_primary_10_1186_s12916_018_1196_2 crossref_primary_10_1186_s13063_020_04334_x crossref_primary_10_1002_sim_8949 crossref_primary_10_1016_j_jclinepi_2022_12_010 crossref_primary_10_1002_sim_70045 crossref_primary_10_1002_sim_8543 crossref_primary_10_1111_all_15945 crossref_primary_10_1002_sim_7851 crossref_primary_10_1080_10543406_2024_2342518 crossref_primary_10_1057_s41270_022_00177_4 crossref_primary_10_1186_s12874_022_01678_7 crossref_primary_10_1080_19466315_2020_1790415 crossref_primary_10_3389_fphar_2025_1548997 crossref_primary_10_3389_fpsyt_2024_1217102 crossref_primary_10_1002_bimj_201700281 crossref_primary_10_1080_03610926_2018_1543770 crossref_primary_10_1186_s12916_018_1017_7 crossref_primary_10_2214_AJR_20_22852 crossref_primary_10_1093_biostatistics_kxw054 crossref_primary_10_5691_jjb_43_37 crossref_primary_10_1002_sim_8034 crossref_primary_10_1002_sim_8430 crossref_primary_10_1002_sim_8953 crossref_primary_10_1002_bimj_201500077 crossref_primary_10_1186_s13063_020_04931_w crossref_primary_10_1080_10543406_2019_1632871 crossref_primary_10_1016_j_softx_2023_101515 crossref_primary_10_1080_10543406_2023_2233590 crossref_primary_10_12688_gatesopenres_12912_2 crossref_primary_10_12688_gatesopenres_12912_1 crossref_primary_10_1002_sim_7910 crossref_primary_10_1007_s10683_022_09773_8 crossref_primary_10_1007_s12561_017_9188_x crossref_primary_10_1002_sim_6823 crossref_primary_10_1016_j_ejca_2023_113278 crossref_primary_10_1080_02664763_2024_2342424 crossref_primary_10_1016_j_clinthera_2020_05_010 crossref_primary_10_1007_s00103_019_02955_5 crossref_primary_10_1186_s13063_023_07654_w crossref_primary_10_1002_1878_0261_12465 crossref_primary_10_1002_sim_10090 crossref_primary_10_1177_1740774517724746 crossref_primary_10_1080_10543406_2023_2204943 crossref_primary_10_1177_1740774516643689 crossref_primary_10_1371_journal_pone_0180131 crossref_primary_10_1080_10543406_2023_2183962 |
Cites_doi | 10.1002/sim.3863 10.1177/009286150103500407 10.1002/sim.3048 10.1111/j.1541-0420.2008.01101.x 10.1002/sim.734 10.1164/rccm.200910-1500OC 10.1111/j.1541-0420.2008.01174.x 10.1177/216847900604000408 10.1002/sim.5377 10.1016/0197-2456(87)90039-0 10.1002/bimj.200390001 10.1002/bimj.200390051 10.1002/(SICI)1097-0258(20000415)19:7<901::AID-SIM405>3.0.CO;2-L 10.1002/sim.1457 10.1198/016214502388618852 10.2307/3109775 10.1080/10543406.2014.925911 10.1002/sim.3436 10.1093/bioinformatics/btm140 10.1080/10543400600614742 10.1093/biomet/93.1.1 10.1002/bimj.200510231 10.1002/sim.2258 10.1097/PCC.0000000000000151 10.1002/sim.6407 10.1002/pst.206 10.1002/sim.2389 10.1016/S0378-3758(99)00032-4 10.1016/S0735-1097(01)01608-4 10.1080/10543406.2011.554129 10.1177/216847900604000409 10.1002/sim.1688 10.1002/sim.2957 10.1002/1521-4036(200111)43:7<821::AID-BIMJ821>3.0.CO;2-F 10.1002/sim.3062 10.1080/01621459.2012.682540 10.1080/10543406.2014.931409 10.1002/047005588X 10.1080/10543406.2011.551336 10.1002/pst.472 10.1002/sim.4202 10.1016/S0197-2456(00)00122-7 10.1177/009286150003400227 10.1002/sim.972 10.1002/(SICI)1097-0258(19980730)17:14<1551::AID-SIM868>3.0.CO;2-E 10.1002/sim.3716 10.1002/sim.3538 10.1080/10543400701645439 10.1002/sim.6192 10.1016/S0197-2456(97)00075-5 10.1002/sim.2966 10.1002/sim.6288 10.1111/j.1541-0420.2010.01507.x 10.32614/CRAN.package.adaptTest 10.1111/j.0006-341X.2001.00886.x 10.1002/(SICI)1521-4036(199906)41:3<261::AID-BIMJ261>3.0.CO;2-U 10.1002/sim.1455 10.1093/biomet/ast035 10.1002/bimj.200510232 10.1186/1745-6215-15-383 10.1002/sim.4780140922 10.1002/(SICI)1521-4036(199910)41:6<689::AID-BIMJ689>3.0.CO;2-P 10.1136/jnnp-2012-302468 10.1002/sim.5361 10.1080/01621459.2011.644141 10.1002/sim.4424 10.1007/978-1-4939-1100-4_8 10.1016/j.jspi.2005.08.014 10.2307/2684438 10.1016/S1359-6446(04)03023-5 10.1002/sim.1136 10.1002/sim.4179 10.1002/sim.4780132309 10.1002/pst.300 10.1002/bimj.200510190 10.1002/sim.5847 10.1002/sim.3704 10.1002/bimj.201300257 10.1080/10543400701645405 10.2307/2531158 10.1038/nrd3079 10.1007/978-3-0348-0709-8_5 10.1002/sim.6272 10.1002/sim.3495 10.1016/j.jspi.2005.08.015 10.1093/biomet/63.3.655 10.1201/EBK1439825488 10.1002/sim.3513 10.1002/sim.6183 10.1177/009286150904300503 10.1002/bimj.201200218 10.1002/sim.1852 10.1002/sim.2180 10.1080/10543406.2013.857238 10.2307/2533262 10.1093/biomet/90.2.367 10.1002/pst.302 10.1002/sim.3559 10.1038/nrd4319 10.1111/j.0006-341X.2004.00246.x 10.1002/sim.5541 10.1111/j.1541-0420.2006.00626.x 10.1111/j.0006-341X.1999.00853.x 10.1002/bimj.200510311 10.1080/19466315.2013.791639 10.1016/j.cct.2013.09.008 10.1002/sim.531 10.1177/2168479013486996 10.1002/sim.1362 10.1177/2168479014522468 10.1002/ddr.20285 10.1007/978-1-4939-1100-4_14 10.1002/pst.1640 10.1002/sim.2251 10.1002/bimj.200510238 10.1002/sim.2725 10.1080/03610929208830947 10.1198/016214502753479374 10.1080/10543400701645215 10.1002/sim.4780110107 10.1002/bimj.200510233 10.1002/sim.5977 10.1002/pst.413 10.2307/2533441 10.1002/bimj.200900003 10.1002/sim.4102 10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>3.0.CO;2-3 10.1002/bimj.4710310600 10.1002/1521-4036(200109)43:5<581::AID-BIMJ581>3.0.CO;2-J 10.1002/bimj.200900207 10.1002/bimj.201200245 10.1056/NEJMoa1404710 10.1016/j.pupt.2010.01.003 10.1111/j.0006-341X.1999.01286.x 10.1177/009286159302700314 10.1198/tast.2011.10213 10.1177/216847900604000412 10.1002/bimj.200710453 10.1161/CIRCULATIONAHA.108.809707 10.1111/j.0006-341X.2004.00221.x 10.1002/sim.1759 10.1016/j.cct.2008.12.002 10.1080/10543406.2014.920869 10.1002/bimj.201000239 10.1002/(SICI)1521-4036(199906)41:3<279::AID-BIMJ279>3.0.CO;2-V 10.2307/2532142 10.1002/bimj.200810442 10.1002/bimj.201300153 10.1002/bimj.200410042 10.1002/sim.4780090113 |
ContentType | Journal Article |
Copyright | 2015 The Authors. Published by John Wiley & Sons Ltd. 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Copyright Wiley Subscription Services, Inc. Feb 10, 2016 |
Copyright_xml | – notice: 2015 The Authors. Published by John Wiley & Sons Ltd. – notice: 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. – notice: Copyright Wiley Subscription Services, Inc. Feb 10, 2016 |
DBID | BSCLL 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 5PM |
DOI | 10.1002/sim.6472 |
DatabaseName | Istex Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Statistics Public Health |
DocumentTitleAlternate | P. BAUER ET AL |
EISSN | 1097-0258 |
EndPage | 347 |
ExternalDocumentID | PMC6680191 3930435301 25778935 10_1002_sim_6472 SIM6472 ark_67375_WNG_TJ0Z7R0Z_6 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Feature |
GeographicLocations | United States--US Europe |
GeographicLocations_xml | – name: Europe – name: United States--US |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 123 1L6 1OB 1OC 1ZS 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABIJN ABJNI ABOCM ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACPOU ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AUFTA AZBYB AZVAB BAFTC BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BSCLL BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P G-S G.N GNP GODZA H.T H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TN5 UB1 V2E W8V W99 WBKPD WH7 WIB WIH WIK WJL WOHZO WQJ WRC WUP WWH WXSBR WYISQ XBAML XG1 XV2 ZZTAW ~IA ~WT 24P AAHQN AAMNL AAYCA ACYXJ AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG AMVHM CITATION CGR CUY CVF ECM EIF NPM AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8 5PM AANHP ACRPL ADNMO |
ID | FETCH-LOGICAL-c6122-821ba94e3e713eafa2a2dcd4576b2230c1f7b17cfd7bc216f09c7c84e107ca3 |
IEDL.DBID | DR2 |
ISSN | 0277-6715 |
IngestDate | Thu Aug 21 18:31:39 EDT 2025 Fri Jul 11 05:38:01 EDT 2025 Sun Jul 13 04:01:15 EDT 2025 Thu Apr 03 06:52:54 EDT 2025 Tue Jul 01 04:46:06 EDT 2025 Thu Apr 24 23:10:55 EDT 2025 Wed Jan 22 16:38:37 EST 2025 Wed Oct 30 09:52:31 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | group sequential designs clinical trials adaptive design |
Language | English |
License | Attribution-NonCommercial http://creativecommons.org/licenses/by-nc/4.0 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c6122-821ba94e3e713eafa2a2dcd4576b2230c1f7b17cfd7bc216f09c7c84e107ca3 |
Notes | istex:E1420A566AD506D638656D0F28A887F9AE0285CE ArticleID:SIM6472 ark:/67375/WNG-TJ0Z7R0Z-6 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-2008-8340 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fsim.6472 |
PMID | 25778935 |
PQID | 1759164194 |
PQPubID | 48361 |
PageCount | 23 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6680191 proquest_miscellaneous_1760903988 proquest_journals_1759164194 pubmed_primary_25778935 crossref_primary_10_1002_sim_6472 crossref_citationtrail_10_1002_sim_6472 wiley_primary_10_1002_sim_6472_SIM6472 istex_primary_ark_67375_WNG_TJ0Z7R0Z_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 10 February 2016 |
PublicationDateYYYYMMDD | 2016-02-10 |
PublicationDate_xml | – month: 02 year: 2016 text: 10 February 2016 day: 10 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: New York – name: Hoboken |
PublicationTitle | Statistics in medicine |
PublicationTitleAlternate | Statist. Med |
PublicationYear | 2016 |
Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc John Wiley and Sons Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
References | Gao P, Liu L, Mehta C. Exact inference for adaptive group sequential designs. Statistics in Medicine 2013; 32(23):3991-4005. Wassmer G. On sample size determination in multi-armed confirmatory adaptive designs. Journal of Biopharmaceutical Statistics 2011; 21:802-817. Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 2008; 50(4):515-527. Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Information Journal 2001; 35:1095-1112. Brannath W, Mehta CR, Posch M. Exact confidence bounds following adaptive group sequential tests. Biometrics 2009; 65(2):539-546. Magirr D, Jaki T, Koenig F, Posch M. Adaptive survival trials. arXiv preprint arXiv:1405.1569 2014. Irle S, Schäfer H. Interim design modificcations in time-to-event studies. Journal of the American Statistical Association 2014; 107:341-348. Schneider S, Schmidli H, Friede T. Blinded sample size re-estimation for recurrent event data with time trends. Statistics in Medicine 2013; 32(30):5448-5457. Bauer P. Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie 1989; 20:130-148. Proschan M, Glimm E, Posch M. Connections between permutation and t-tests: relevance to adaptive methods. Statistics in Medicine 2014; 33(27):4734-4742. Magirr D, Jaki T, Posch M, Klinglmüller F. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs. Biometrika 2013; 100(4):985-996. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22(5):689-703. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic Press: New York, 1985. Denne JS. Sample size recalculation using conditional power. Statistics in Medicine 2001; 20:2645-2660. König F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Statistics in Medicine 2008; 27:1612-1625. Timmesfeld N, Schäfer H, Müller H-H. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate. Statistics in Medicine 2007; 26(12):2449-2464. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55(4):1286-1290. Phillips AJ, Keene ON. Adaptive designs for pivotal trials: discussion points from the PSI adaptive design expert group. Pharmaceutical Statistics 2006; 5(1):61-66. Schmidli H, Bretz F, Racine-Poon A. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Statistics in Medicine 2007; 26(27):4925-4938. Burman C-F, Sonesson C. Are flexible designs sound? Biometrics 2006; 62(3):664-669. FDA. Draft Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER): Rockville MD, USA, 2010. url=http://http://www.fda.gov/. Gutjahr G, Brannath W, Bauer P. An approach to the conditional error rate principle with nuisance parameters. Biometrics 2011; 67(3):1039-1046. Goll A, Bauer P. Two-stage designs applying methods differing in costs. Bioinformatics 2007; 23(12):1519-1526. Chuang-Stein C, Bretz F, Komiyama O, Quinlan J. Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs. Regulatory Affairs Focus 2009; 14(4):36-42. Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, Papaluca-Amati M, Posch M. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials 2014; 15(1):383. Coburger S, Wassmer G. Conditional point estimation in adaptive group sequential test designs. Biometrical Journal 2001; 43(7):821-833. Brannath W, König F, Bauer P. Estimation in flexible two stage designs. Statistics in Medicine 2006; 25(19):3366-3381. Brannath W, Bauer P, Posch M. On the efficiency of adaptive designs for flexible interim decisions in clinical trials. Journal of Statistical Planning and Inference 2006; 136(6):1956-1961. Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 2004; 23:2497-2508. Graf A, Posch M, Koenig F. Adaptive designs for subpopulation analysis optimizing utility functions. Biometrical Journal 2015; 57(1):76-89. Barnes PJ, Pocock SJ, Magnussen H. Integrating indacaterol dose selection in a clinical study in copd using an adaptive seamless design. Pulmonary Pharmacology & Therapeutics 2010; 23:165-171. Dragalin V. Adaptive designs: Terminology and classification. Drug Information Journal 2006; 40:425-435. Hünseler C, Balling G, Röhlig C, Blickheuser R, Trieschmann U, Lieser U, Dohna-Schwake C, Gebauer C, Möller O, Hering F, Hoehn T., Schubert S, Hentschel R, Huth RG, Müller A, Müller C, Wassmer G, Hahn M, Harnischmacher U, Behr J, Roth B. Continuous infusion of clonidine in ventilated newborns and infants: A randomized controlled trial. Pediatric Critical Care Medicine 2014; 15:511-522. Lehmacher W, Kieser M, Hothorn L. Sequential and multiple testing for dose-response analysis. Drug Information Journal 2000; 34:591-597. PhRMA Working Group on Adaptive Designs. White papers. Drug Information Journal 2006; 40(22):421-484. Bauer P, Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discovery Today 2004; 9:351-357. Müller H-H, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57:886-891. Hung HMJ, Wang S-J, Yang P. Some challenges with statistical inference in adaptive designs. Journal of Biopharmaceutical Statistics 2014; 24(5):1059-1072. Bowden J, Glimm E. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials. Biometrical Journal 2014; 56(2):332-349. Lawrence J, Hung HM. Estimation and confidence intervals after adjusting the maximum information. Biometrical Journal 2003; 45(2):143-152. Wassmer G, Reitmeir P, Kieser M, Lehmacher W. Procedures for testing multiple endpoints in clinical trials: An overview. Journal of Statistical Planning and Inference 1999; 82:69-81. Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90:367-378. Bauer J, Einfalt P. Application of adaptive designs - a review. Biometrical Journal 2006; 8:1-16. Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Information Journal 2006; 40:437-444. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design sequential, adaptive, and enrichment strategies. Circulation 2009; 119(4):597-605. Wassmer G, Dragalin V. Designing issues in confirmatory adaptive population enrichment trials. Journal of Biopharmaceutical Statistics 2015; 25:early view. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63:655-660. Scherag A, Hebebrand J, Schäfer H, Müller H-H. Flexible designs for genomewide association studies. Biometrics 2009; 65(3):815-821. Proschan M, Lan G, Wittes J. Statistical Monitoring of Clinical Trials. A Unified Approach. Springer: Science & Business Media, 2006. Klinglmueller F, Posch M, Koenig F. Adaptive graph-based multiple testing procedures. Pharmaceutical Statistics 2014; 13(6):345-356. Gould AL. Planning and revising the sample size for a trial. Statistics in Medicine 1995; 14:1039-1051. Cui L, Hung HMJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857. Wassmer G. A comparison of two methods for adaptive interim analyses in clinical trials. Biometrics 1998; 54:696-705. Stallard N, Hamborg T, Parsons N, Friede T. Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 2014; 24(1):168-187. Emerson SS. Statistical packages for group sequential methods. The American Statistician 1996; 50:183-192. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 2011; 30(28):3267-3284. Faldum A, Hommel G. Strategies for including patients recruited during interim analysis of clinical trials. Journal of Biopharmaceutical Statistics 2007; 17(6):1211-1225. Desseaux K, Porcher R. Flexible two-stage design with sample size reassessment for survival trials. Statistics in Medicine 2007; 26(27):5002-5013. Hartung J. A self-designing rule for clinical trials with arbitrary variables. Controlled Clinical Trials 2001; 22:111-116. Wang S-J, Brannath W, Brückner M, James Hung HM, Koch A. Unblinded adaptive statistical information design based on clinical endpoint or biomarker. Statistics in Biopharmaceutical Research 2013; 5(4):293-310. Graf AC, Bauer P, Glimm E, Koenig F. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications. Biometrical Journal 2014; 56(4):614-630. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-1087. Chang M. Adaptive Design Theory and Implementation Using SAS and R. Chapman and Hall/CRC: Boca Raton, London, New York, 2008. Antonijevic Z, Gallo G, Chuang-Stein C, Dragalin V, Loewy J, Menon S, Miller ER, CC Morgan, Sanchez M. Views on emerging issues pertaining to data monitoring committees for adaptive trials. Therapeutic Innovation & Regulatory Science 2013; 47:495-502. Brannath W, Gutjahr G, Bauer P. Probabilistic foundation of confirmatory adaptive designs. Journal of the American Statistical Association 2012; 107:824-832. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50:1029-1041, correc 1976; 63 1993; 27 2002; 97 2015; 72 2004; 23 2004; 9 2011; 53 2014; 24 1999; 41 2014; Accepted 2010; 182 2009; 119 2013; 5 2005; 2443 2001; 43 2010; 23 2009; 14 1998; 17 2000; 19 1989; 31 2013; 55 2010; 29 2015; Early View 2006; 25 2008; 27 2014; 15 1999; 55 1985 2007; 6 2014; 13 2011; 65 2011; 67 2001; 57 2010; 9 2003; 45 2007; 17 2015; 57 1984; 40 1995; 51 2009; 65 2004; 46 1998 2013; 100 2014; 48 2001; 22 2008; 50 2012; 107 2012; 31 2001; 20 1999 2006; 40 2009; 70 2006; 48 1994; 13 2001; 38 1992; 21 1990; 9 2001; 35 2010; 52 2014; 33 2003; 22 2009; 43 2004; 60 1987; 8 2011; 10 1999; 82 1992; 11 2006; 136 2003; 90 2009; 51 2014; 3 1991; 47 2006; 62 2000 1999; 18 1997; 18 2011; 21 1998; 54 2007; 23 2014; 56 2007; 26 2012; 83 2006; 93 2013; 47 1989; 20 2012 2010 1995; 14 2006; 16 1996; 50 2009 2011; 30 2006; 8 2008 2007 2006; 5 2006 2009; 28 2014; 107 2015; 25 2009; 30 2013; 36 2013; 32 2000; 34 2015 2014 2013 1994; 50 2007; 49 e_1_2_9_75_1 e_1_2_9_98_1 e_1_2_9_52_1 e_1_2_9_79_1 Heritier S (e_1_2_9_146_1) 2015 e_1_2_9_94_1 e_1_2_9_10_1 e_1_2_9_56_1 e_1_2_9_33_1 e_1_2_9_90_1 e_1_2_9_71_1 e_1_2_9_126_1 e_1_2_9_149_1 e_1_2_9_107_1 e_1_2_9_122_1 e_1_2_9_145_1 e_1_2_9_168_1 e_1_2_9_14_1 Lawrence D (e_1_2_9_142_1) 2014 e_1_2_9_37_1 e_1_2_9_164_1 e_1_2_9_18_1 e_1_2_9_160_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_87_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_68_1 e_1_2_9_83_1 Carreras M (e_1_2_9_103_1) 2015 e_1_2_9_6_1 e_1_2_9_119_1 e_1_2_9_60_1 e_1_2_9_138_1 e_1_2_9_111_1 Hedges LV (e_1_2_9_35_1) 1985 e_1_2_9_134_1 e_1_2_9_115_1 e_1_2_9_157_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_130_1 e_1_2_9_176_1 e_1_2_9_153_1 e_1_2_9_172_1 e_1_2_9_30_1 e_1_2_9_53_1 e_1_2_9_99_1 Chang M (e_1_2_9_167_1) 2008 e_1_2_9_72_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_57_1 e_1_2_9_95_1 Chuang‐Stein C (e_1_2_9_132_1) 2009; 14 e_1_2_9_76_1 PhRMA Working Group on Adaptive Designs (e_1_2_9_131_1) 2006; 40 e_1_2_9_102_1 e_1_2_9_148_1 e_1_2_9_129_1 e_1_2_9_144_1 e_1_2_9_125_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_140_1 e_1_2_9_163_1 e_1_2_9_121_1 e_1_2_9_19_1 e_1_2_9_88_1 e_1_2_9_61_1 e_1_2_9_46_1 e_1_2_9_84_1 Bauer P (e_1_2_9_2_1) 1989; 20 e_1_2_9_23_1 e_1_2_9_65_1 Tymofyeyev Y (e_1_2_9_156_1) 2014 e_1_2_9_80_1 e_1_2_9_5_1 e_1_2_9_114_1 e_1_2_9_137_1 Sugitani T (e_1_2_9_91_1) 2014 e_1_2_9_118_1 e_1_2_9_179_1 e_1_2_9_9_1 e_1_2_9_175_1 e_1_2_9_27_1 e_1_2_9_69_1 Magirr D (e_1_2_9_100_1) 2014 e_1_2_9_110_1 e_1_2_9_171_1 Bauer J (e_1_2_9_133_1) 2006; 8 Gallo P (e_1_2_9_141_1) 2014 e_1_2_9_31_1 e_1_2_9_50_1 e_1_2_9_73_1 Jennison C (e_1_2_9_105_1) 2000 e_1_2_9_77_1 e_1_2_9_96_1 e_1_2_9_12_1 Wassmer G (e_1_2_9_42_1) 1999 e_1_2_9_54_1 e_1_2_9_92_1 e_1_2_9_109_1 EMA (e_1_2_9_7_1) 2007 Bauer P (e_1_2_9_36_1) 1989; 31 Proschan M (e_1_2_9_106_1) 2006 e_1_2_9_101_1 e_1_2_9_128_1 e_1_2_9_166_1 e_1_2_9_39_1 e_1_2_9_162_1 e_1_2_9_120_1 e_1_2_9_16_1 e_1_2_9_58_1 e_1_2_9_20_1 e_1_2_9_62_1 e_1_2_9_89_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_66_1 e_1_2_9_85_1 Chen JJ (e_1_2_9_124_1) 2014; 3 e_1_2_9_81_1 e_1_2_9_4_1 e_1_2_9_113_1 e_1_2_9_159_1 e_1_2_9_117_1 e_1_2_9_155_1 e_1_2_9_136_1 e_1_2_9_178_1 e_1_2_9_151_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_174_1 e_1_2_9_170_1 e_1_2_9_74_1 e_1_2_9_51_1 e_1_2_9_78_1 Chaturvedi PR (e_1_2_9_147_1) 2014 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_55_1 e_1_2_9_97_1 Lawrence D (e_1_2_9_143_1) 2014 e_1_2_9_93_1 e_1_2_9_108_1 e_1_2_9_70_1 e_1_2_9_127_1 e_1_2_9_123_1 e_1_2_9_169_1 FDA (e_1_2_9_8_1) 2010 e_1_2_9_104_1 e_1_2_9_17_1 e_1_2_9_59_1 e_1_2_9_165_1 e_1_2_9_161_1 e_1_2_9_180_1 EMA (e_1_2_9_152_1) 2006 e_1_2_9_40_1 e_1_2_9_21_1 e_1_2_9_67_1 e_1_2_9_44_1 e_1_2_9_86_1 e_1_2_9_82_1 e_1_2_9_3_1 Posch M (e_1_2_9_63_1) 2005; 2443 e_1_2_9_112_1 e_1_2_9_139_1 e_1_2_9_116_1 e_1_2_9_135_1 e_1_2_9_158_1 e_1_2_9_177_1 e_1_2_9_25_1 e_1_2_9_154_1 e_1_2_9_173_1 e_1_2_9_48_1 e_1_2_9_29_1 e_1_2_9_150_1 26757956 - Stat Med. 2016 Feb 10;35(3):364-7 26757952 - Stat Med. 2016 Feb 10;35(3):348-9 26757953 - Stat Med. 2016 Feb 10;35(3):350-8 26757955 - Stat Med. 2016 Feb 10;35(3):362-3 26757954 - Stat Med. 2016 Feb 10;35(3):359-61 |
References_xml | – reference: Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts. Biometrical Journal 2006; 48(4):623-634. – reference: Cheng Y, Shen Y. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials. Biometrics 2004; 60(4):910-918. – reference: Goll A, Bauer P. Two-stage designs applying methods differing in costs. Bioinformatics 2007; 23(12):1519-1526. – reference: Wassmer G, Dragalin V. Designing issues in confirmatory adaptive population enrichment trials. Journal of Biopharmaceutical Statistics 2015; 25:early view. – reference: Proschan M, Glimm E, Posch M. Connections between permutation and t-tests: relevance to adaptive methods. Statistics in Medicine 2014; 33(27):4734-4742. – reference: PhRMA Working Group on Adaptive Designs. White papers. Drug Information Journal 2006; 40(22):421-484. – reference: Jennison C, Turnbull BW. Adaptive and nonadaptive group sequential tests. Biometrika 2006; 93:1-21. – reference: Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. Journal of Neurology Neurosurgery and Psychiatry 2012; 83(11):1125-1132. – reference: Bauer P, König F. The reassessment of trial perspectives from interim data - a critical view. Statistics In Medicine 2006; 25:23-36. – reference: Hartung J. A self-designing rule for clinical trials with arbitrary variables. Controlled Clinical Trials 2001; 22:111-116. – reference: Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50:1029-1041, correction in Biometrics 1996, 52:380. – reference: Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Statistics in Medicine 2000; 19:901-911. – reference: Gutjahr G, Brannath W, Bauer P. An approach to the conditional error rate principle with nuisance parameters. Biometrics 2011; 67(3):1039-1046. – reference: Burman C-F, Sonesson C, Guilbaud O. A recycling framework for the construction of Bonferroni-based multiple tests. Statistics in Medicine 2009; 28(5):739-761. – reference: EMA. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. European Medicines Agency: London, UK, 2007. http://www.ema.europa.eu. – reference: Posch M, Bauer P, Brannath W. Issues in designing flexible trials. Statistics in Medicine 2003; 22(6):953-969. – reference: Wang S-J, Hung HM, O'Neil RT. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials. Biometrical Journal 2010; 52(6):798-810. – reference: Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs - background, operational aspects, and examples. Drug Information Journal 2006; 40:463-473. – reference: Victor A, Hommel G. Combining adaptive designs with control of the false discovery rate-a generalized definition for a global p-value. Biometrical Journal 2007; 49(1):94-106. – reference: Chuang-Stein C, Bretz F, Komiyama O, Quinlan J. Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs. Regulatory Affairs Focus 2009; 14(4):36-42. – reference: Burman C-F, Sonesson C. Are flexible designs sound? Biometrics 2006; 62(3):664-669. – reference: Graf AC, Bauer P, Glimm E, Koenig F. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications. Biometrical Journal 2014; 56(4):614-630. – reference: Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 2008; 50(4):515-527. – reference: Wang S-J, Hung HMJ, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 2009; 51(2):358-374. – reference: Bauer P. Sequential tests of hypotheses in consecutive trials. Biometrical Journal 1989; 31:663-676. – reference: Jennison C, Turnbull BW. Adaptive seamless designs: selection and prospective testing of hypotheses. Journal of Biopharmaceutical Statistics 2007; 17(6):1135-1161. – reference: O'Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Controlled Clinical Trials 1997; 18:550-556. – reference: Gould AL. Interim analysis for monitoring clinical trials that do not materially affect the type I error rate. Statistics in Medicine 1992; 11:53-66. – reference: Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine-Poon A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy on oncology. Statistics in Medicine 2009; 28:1445-1463. – reference: Lehmacher W, Kieser M, Hothorn L. Sequential and multiple testing for dose-response analysis. Drug Information Journal 2000; 34:591-597. – reference: Chen JJ, Lu T-P, Chen D-T, Wang S-J. Biomarker adaptive designs in clinical trials. Translational Cancer Research 2014; 3(3):279-292. – reference: Denne JS. Sample size recalculation using conditional power. Statistics in Medicine 2001; 20:2645-2660. – reference: König F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Statistics in Medicine 2008; 27:1612-1625. – reference: Timmesfeld N, Schäfer H, Müller H-H. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate. Statistics in Medicine 2007; 26(12):2449-2464. – reference: Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine 2009; 28(4):586-604. – reference: Wang S-J, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 2007; 6(3):227-244. – reference: Glimm E. Comments on Adaptive increase in sample size when interim results are promising: A practical guide with examples by CR Mehta and SJ Pocock. Statistics in Medicine 2012; 31(1):98-99. – reference: Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 2012; 31(30):4309-4320. – reference: Posch M, König F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimating in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 2443:3697-3714. – reference: Wang S-J, Hung HM. Adaptive enrichment with subpopulation selection at interim: Methodologies, applications and design considerations. Contemporary Clinical Trials 2013; 36(2):673-681. – reference: Brannath W, Gutjahr G, Bauer P. Probabilistic foundation of confirmatory adaptive designs. Journal of the American Statistical Association 2012; 107:824-832. – reference: Klinglmueller F, Posch M, Koenig F. Adaptive graph-based multiple testing procedures. Pharmaceutical Statistics 2014; 13(6):345-356. – reference: Bauer P, Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discovery Today 2004; 9:351-357. – reference: Graf A, Posch M, Koenig F. Adaptive designs for subpopulation analysis optimizing utility functions. Biometrical Journal 2015; 57(1):76-89. – reference: Case LD, Morgan TM, Davis CE. Optimal restricted two-stage designs. Controlled Clinical Trials 1987; 8:146-156. – reference: Wassmer G. Multistage adaptive test procedures based on Fisher's product criterion. Biometrical Journal 1999; 41:279-293. – reference: Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Information Journal 2006; 40:437-444. – reference: Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22(5):689-703. – reference: Antonijevic Z, Gallo G, Chuang-Stein C, Dragalin V, Loewy J, Menon S, Miller ER, CC Morgan, Sanchez M. Views on emerging issues pertaining to data monitoring committees for adaptive trials. Therapeutic Innovation & Regulatory Science 2013; 47:495-502. – reference: Schmidli H, Bretz F, Racine-Poon A. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Statistics in Medicine 2007; 26(27):4925-4938. – reference: Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, U Tebbe, Schröder R, Tiemann R, Machnig T, Neuhaus KL. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (escami) trial. Journal of the American College of Cardiology 2001; 38(6):E1644-E1650. – reference: Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biometrical Journal 2006; 48(4):537-555. – reference: Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Information Journal 2001; 35:1095-1112. – reference: Friede T, Parsons N, Stallard N, Todd S, Valdes Marquez E, Chataway J, Nicholas R. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine 2011; 30(13):1528-1540. – reference: Cui L, Hung HMJ, Wang S-J. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857. – reference: Brannath W, Bauer P, Posch M. On the efficiency of adaptive designs for flexible interim decisions in clinical trials. Journal of Statistical Planning and Inference 2006; 136(6):1956-1961. – reference: Posch M, Bauer P. Adaptive two stage designs and the conditional error function. Biometrical Journal 1999; 41:689-696. – reference: O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-1087. – reference: Tamhane AC, Wu Y, Mehta CR. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (ii): sample size re-estimation. Statistics in Medicine 2012; 31(19):2041-2054. – reference: Desseaux K, Porcher R. Flexible two-stage design with sample size reassessment for survival trials. Statistics in Medicine 2007; 26(27):5002-5013. – reference: Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect sizes under consideration. Statistics in Medicine 2006; 25(6):917-932. – reference: Barnes PJ, Pocock SJ, Magnussen H. Integrating indacaterol dose selection in a clinical study in copd using an adaptive seamless design. Pulmonary Pharmacology & Therapeutics 2010; 23:165-171. – reference: Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Statistics in Medicine 1990; 9:65-72. – reference: Kieser M, Bauer P, Lehmacher W. Inference on multiple endpoints in clinical trials with adaptive interim analyses. Biometrical Journal 1999; 41:261-277. – reference: Gao P, Liu L, Mehta C. Adaptive sequential testing for multiple comparisons. Journal of Biopharmaceutical Statistics 2014; 24(5):1035-1058. – reference: Heritier S, Lô SN, Morgan CC. An adaptive confirmatory trial with treatment selection: practical experiences and unbalanced randomization. Statistics in Medicine 2011; 30:1541-1554. – reference: Hung HMJ, Wang S-J, Yang P. Some challenges with statistical inference in adaptive designs. Journal of Biopharmaceutical Statistics 2014; 24(5):1059-1072. – reference: Friede T, Kieser M. A comparison of methods for adaptive sample size adjustment. Statistics in Medicine 2001; 20(24):3861-3873. – reference: Brannath W, Koenig F, Bauer P. Multiplicity and flexibility in clinical trials. Pharmaceutical Statistics 2007; 6(3):205-216. – reference: Hu F, Rosenberger WF. The Theory of Response-Adaptive Randomization in Clinical trials. John Wiley & Sons: Hoboken, 2006. – reference: Magirr D, Jaki T, Posch M, Klinglmüller F. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs. Biometrika 2013; 100(4):985-996. – reference: Posch M, Proschan MA. Unplanned adaptations before breaking the blind. Statistics in Medicine 2012; 31(30):4146-4153. – reference: Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA working group. Journal of Biopharmaceutical Statistics 2006; 16:275-283. – reference: Brannath W, Posch M, Bauer P. Recursive combination tests. Journal of the American Statistical Association 2002; 97:236-244. – reference: Birkett MA, Day SJ. Internal pilot studies for estimating sample size. Statistics in Medicine 1994; 13:2455-2463. – reference: Jahn-Eimermacher A, Ingel K. Adaptive trial design: A general methodology for censored time to event data. Contemporary Clinical Trials 2009; 30(2):171-177. – reference: Jennison C, Turnbull BW. Mid-course sample size modification in clinical trial. Statistics in Medicine 2003; 22:971-993. – reference: Liu Q, Proschan MA, Pledger GW. A unified theory of two-stage adaptive designs. Journal of the American Statistical Association 2002; 97:1034-1041. – reference: Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC: Boca Raton, London, New York, Washington, D.C., 2000. – reference: Müller H-H, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57:886-891. – reference: Brannath W, König F, Bauer P. Estimation in flexible two stage designs. Statistics in Medicine 2006; 25(19):3366-3381. – reference: Gould AL. Planning and revising the sample size for a trial. Statistics in Medicine 1995; 14:1039-1051. – reference: Schneider S, Schmidli H, Friede T. Blinded sample size re-estimation for recurrent event data with time trends. Statistics in Medicine 2013; 32(30):5448-5457. – reference: Gao P, Liu L, Mehta C. Exact inference for adaptive group sequential designs. Statistics in Medicine 2013; 32(23):3991-4005. – reference: Chen YH, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 2004; 23(7):1023-1038. – reference: Mehta C, Gao P. Population enrichment designs: case study of a large multinational trial. Journal of Biopharmaceutical Statistics 2011; 21(4):831-845. – reference: Bretz F, Posch M, Glimm E, Klinglmüller F, Maurer W, Rohmeyer K. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biometrical Journal 2011; 53(6):894-913. – reference: Wassmer G. On sample size determination in multi-armed confirmatory adaptive designs. Journal of Biopharmaceutical Statistics 2011; 21:802-817. – reference: Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 2004; 23:2497-2508. – reference: Gaydos B, Anderson KM, Berry D, Burnham N, Chuang-Stein C, Dudinak J, Fardipour P, P Gallo, Givens S, Lewis R, Maca J, Pinheiro J, Pritchett Y, Krams M. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal 2009; 43:539-565. – reference: Dragalin V. Adaptive designs: Terminology and classification. Drug Information Journal 2006; 40:425-435. – reference: Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 2011; 30(28):3267-3284. – reference: Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate. Biometrics 1991; 47(2):511-521. – reference: Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, RJ Phillips, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Febrer Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, J Bernabeu-Wittel, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, S Heritier, Delarue A, Voisard JJ. A randomized controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine 2015; 72(8):735-746. – reference: Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51:1315-1324. – reference: Magirr D, Stallard N, Jaki T. Flexible sequential designs for multi-arm clinical trials. Statistics in Medicine 2014; 33:3269-3279. – reference: EMA. Guideline on Clinical Trials in Small Populations (chmp/ewp/83561/2005). European Medicines Agency: London, UK, 2006. http://www.ema.europa.eu. – reference: Bretz F, Branson M, Burman CF, Chuang-Stein C, Coffey CS. Adaptivity in drug discovery and development. Drug Development Research 2009; 70:169-190. – reference: Wassmer G, Vandemeulebroecke M. A brief review on software developments for group sequential and adaptive designs. Biometrical Journal 2006; 48(4):732-737. – reference: Chang M. Adaptive Design Theory and Implementation Using SAS and R. Chapman and Hall/CRC: Boca Raton, London, New York, 2008. – reference: Stallard N, Friede T. A group-sequential design for clinical trials with treatment selection. Statistics in Medicine 2008; 27:6209-6227. – reference: Lawrence J, Hung HM. Estimation and confidence intervals after adjusting the maximum information. Biometrical Journal 2003; 45(2):143-152. – reference: Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63:655-660. – reference: Carreras M, Gutjahr G, Brannath W. Adaptive seamless designs with interim treatment selection: a case study in oncology. Statistics in Medicine 2015; Early View. – reference: Mehta C, Schäfer H, Daniel H, Irle S. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Statistics in Medicine 2014; 33(26):4515-4531. – reference: Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10:347-356. – reference: Bauer P, König F. The risks of methodology aversion in drug regulation. Nature Reviews Drug Discovery 2014; 13(5):317-318. – reference: Sugitani T, Bretz F, Maurer W. A simple and flexible graphical approach for adaptive group-sequential clinical trials. Journal of Biopharmaceutical Statistics 2014; Accepted. – reference: Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Communications in Statistics - Theory and Methods 1992; 21:2833-2853. – reference: Bauer P, Posch M. Letter to the Editor: Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections. Statistics in Medicine 2004; 23:1333-1335. – reference: Bauer P. Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie 1989; 20:130-148. – reference: Hung HMJ, Wang S-J, O'Neill R. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. Journal of Biopharmaceutical Statistics 2007; 17(6):1201-1210. – reference: Sugitani T, Hamasaki T, Hamada C. Partition testing in confirmatory adaptive designs with structured objectives. Biometrical Journal 2013; 55(3):341-359. – reference: Wassmer G. A comparison of two methods for adaptive interim analyses in clinical trials. Biometrics 1998; 54:696-705. – reference: Posch M, Maurer W, Bretz F. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. Pharmaceutical Statistics 2011; 10(2):96-104. – reference: Emerson SS. Statistical packages for group sequential methods. The American Statistician 1996; 50:183-192. – reference: Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18:1833-1848. – reference: Phillips AJ, Keene ON. Adaptive designs for pivotal trials: discussion points from the PSI adaptive design expert group. Pharmaceutical Statistics 2006; 5(1):61-66. – reference: Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design sequential, adaptive, and enrichment strategies. Circulation 2009; 119(4):597-605. – reference: Wang S-J, Brannath W, Brückner M, James Hung HM, Koch A. Unblinded adaptive statistical information design based on clinical endpoint or biomarker. Statistics in Biopharmaceutical Research 2013; 5(4):293-310. – reference: Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, Papaluca-Amati M, Posch M. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials 2014; 15(1):383. – reference: Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55(4):1286-1290. – reference: Magirr D, Jaki T, Koenig F, Posch M. Adaptive survival trials. arXiv preprint arXiv:1405.1569 2014. – reference: Bauer P, Koenig F, Brannath W, Posch M. Selection and bias - two hostile brothers. Statistics in Medicine 2010; 29(1):1-13. – reference: Coburger S, Wassmer G. Sample size reassessment in adaptive clinical trials using a bias corrected estimate. Biometrical Journal 2003; 45(7):812-825. – reference: Bretz F, König F, Brannath W, Glimm E, Posch M. Tutorial in biostatistics: Adaptive designs for confirmatory clinical trials. Statistics in Medicine 2009; 28:1181-1217. – reference: Irle S, Schäfer H. Interim design modificcations in time-to-event studies. Journal of the American Statistical Association 2014; 107:341-348. – reference: Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 2001; 43:581-589. – reference: Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90:367-378. – reference: Shun Z, Yuan W, Brady WE, Hsu H. Type I error in sample size re-estimations based on observed treatment difference. Statistics in Medicine 2001; 20(4):497-513. – reference: Friede Tim, Stallard Nigel. A comparison of methods for adaptive treatment selection. Biometrical Journal 2008; 50(5):767-781. – reference: Gugerli US, Maurer W, Mellein B. Internally adaptive designs for parallel group trials. Drug Information Journal 1993; 27:721-732. – reference: Zhou J, Adewale A, Shentu Y, Liu J, Anderson K. Information-based sample size re-estimation in group sequential design for longitudinal trials. Statistics in Medicine 2014; 33(22):3801-3814. – reference: Bowden J, Glimm E. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials. Biometrical Journal 2014; 56(2):332-349. – reference: Brannath W, Bauer P. Optimal conditional error functions for the control of conditional power. Biometrics 2004; 60:715-723. – reference: Morgan C, Huyck S, Jenkins M, Chen L, Bedding A, Coffey C, Gaydos B, Wathen J. Adaptive design: Results of 2012 survey on perception and use. Therapeutic Innovation & Regulatory Science 2014; 48:473-481. – reference: Bauer J, Einfalt P. Application of adaptive designs - a review. Biometrical Journal 2006; 8:1-16. – reference: Posch M, Timmesfeld N, König F, Müller H-H. Conditional rejection probabilities of Student's t-test and design adaptation. Biometrical Journal 2004; 46:389-403. – reference: Wassmer G, Reitmeir P, Kieser M, Lehmacher W. Procedures for testing multiple endpoints in clinical trials: An overview. Journal of Statistical Planning and Inference 1999; 82:69-81. – reference: Schäfer H, Müller H-H. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections. Statistics in Medicine 2001; 20:3741-3751. – reference: Burman C-F, Lisovskaja V. The dual test: Safeguarding p-value combination tests for adaptive designs. Statistics in Medicine 2010; 29(7-8):797-807. – reference: Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic Press: New York, 1985. – reference: Brannath W, Mehta CR, Posch M. Exact confidence bounds following adaptive group sequential tests. Biometrics 2009; 65(2):539-546. – reference: Mehta CR, Bauer P, Posch M, Brannath W. Repeated confidence intervals for adaptive group sequential trials. Statistics in Medicine 2007; 26(30):5422-5433. – reference: Schmidli H, Bretz F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biometrical Journal 2006; 48(4):635-643. – reference: Zhu L, Ni L, Yao B. Group sequential methods and software applications. The American Statistician 2011; 65:127-135. – reference: Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials. CRC Press: Boca Raton, 2010. – reference: Scherag A, Hebebrand J, Schäfer H, Müller H-H. Flexible designs for genomewide association studies. Biometrics 2009; 65(3):815-821. – reference: Proschan M, Lan G, Wittes J. Statistical Monitoring of Clinical Trials. A Unified Approach. Springer: Science & Business Media, 2006. – reference: Donohue JF, Fogarty C, Lötvall J. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine 2010; 182:155-162. – reference: Liu Q, Pledger GW. On design and inference for two-stage adaptive clinical trials with dependent data. Journal of Statistical Planning and Inference 2006; 136:1962-1984. – reference: Faldum A, Hommel G. Strategies for including patients recruited during interim analysis of clinical trials. Journal of Biopharmaceutical Statistics 2007; 17(6):1211-1225. – reference: Stallard N. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Statistics in Medicine 2010; 29(9):959-971. – reference: Hünseler C, Balling G, Röhlig C, Blickheuser R, Trieschmann U, Lieser U, Dohna-Schwake C, Gebauer C, Möller O, Hering F, Hoehn T., Schubert S, Hentschel R, Huth RG, Müller A, Müller C, Wassmer G, Hahn M, Harnischmacher U, Behr J, Roth B. Continuous infusion of clonidine in ventilated newborns and infants: A randomized controlled trial. Pediatric Critical Care Medicine 2014; 15:511-522. – reference: Eichler H-G, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nature Reviews Drug Discovery 2010; 9(4):277-291. – reference: Stallard N, Hamborg T, Parsons N, Friede T. Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 2014; 24(1):168-187. – reference: Wassmer G. Planning and analyzing adaptive group sequential survival trials. Biometrical Journal 2006; 48(4):714-729. – reference: Fisher LD. Self-designing clinical trials. Statistics in Medicine 1998; 17:1551-1562. – reference: Wassmer G. Statistische Testverfahren für gruppensequentielle und adaptive Pläne in klinischen Studien. Theoretische Konzepte und deren praktische Umsetzung mit SAS. Verlag Alexander Mönch: Köln, 1999. – reference: Coburger S, Wassmer G. Conditional point estimation in adaptive group sequential test designs. Biometrical Journal 2001; 43(7):821-833. – reference: FDA. Draft Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER): Rockville MD, USA, 2010. url=http://http://www.fda.gov/. – volume: 43 start-page: 581 year: 2001 end-page: 589 article-title: Adaptive modifications of hypotheses after an interim analysis publication-title: Biometrical Journal – volume: 33 start-page: 4515 issue: 26 year: 2014 end-page: 4531 article-title: Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints publication-title: Statistics in Medicine – volume: 29 start-page: 959 issue: 9 year: 2010 end-page: 971 article-title: A confirmatory seamless phase II/III clinical trial design incorporating short‐term endpoint information publication-title: Statistics in Medicine – volume: 62 start-page: 664 issue: 3 year: 2006 end-page: 669 article-title: Are flexible designs sound? publication-title: Biometrics – volume: 27 start-page: 1612 year: 2008 end-page: 1625 article-title: Adaptive Dunnett tests for treatment selection publication-title: Statistics in Medicine – volume: 28 start-page: 1445 year: 2009 end-page: 1463 article-title: Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy on oncology publication-title: Statistics in Medicine – volume: 23 start-page: 1023 issue: 7 year: 2004 end-page: 1038 article-title: Increasing the sample size when the unblinded interim result is promising publication-title: Statistics in Medicine – volume: 31 start-page: 4146 issue: 30 year: 2012 end-page: 4153 article-title: Unplanned adaptations before breaking the blind publication-title: Statistics in Medicine – volume: 27 start-page: 6209 year: 2008 end-page: 6227 article-title: A group‐sequential design for clinical trials with treatment selection publication-title: Statistics in Medicine – volume: 40 start-page: 425 year: 2006 end-page: 435 article-title: Adaptive designs: Terminology and classification publication-title: Drug Information Journal – volume: 33 start-page: 4734 issue: 27 year: 2014 end-page: 4742 article-title: Connections between permutation and t‐tests: relevance to adaptive methods publication-title: Statistics in Medicine – volume: 54 start-page: 696 year: 1998 end-page: 705 article-title: A comparison of two methods for adaptive interim analyses in clinical trials publication-title: Biometrics – volume: 25 start-page: 23 year: 2006 end-page: 36 article-title: The reassessment of trial perspectives from interim data – a critical view publication-title: Statistics In Medicine – volume: 45 start-page: 143 issue: 2 year: 2003 end-page: 152 article-title: Estimation and confidence intervals after adjusting the maximum information publication-title: Biometrical Journal – volume: 10 start-page: 347 year: 2011 end-page: 356 article-title: An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints publication-title: Pharmaceutical Statistics – volume: 25 start-page: 3366 issue: 19 year: 2006 end-page: 3381 article-title: Estimation in flexible two stage designs publication-title: Statistics in Medicine – volume: 136 start-page: 1962 year: 2006 end-page: 1984 article-title: On design and inference for two‐stage adaptive clinical trials with dependent data publication-title: Journal of Statistical Planning and Inference – volume: 17 start-page: 1201 issue: 6 year: 2007 end-page: 1210 article-title: Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials publication-title: Journal of Biopharmaceutical Statistics – volume: 6 start-page: 205 issue: 3 year: 2007 end-page: 216 article-title: Multiplicity and flexibility in clinical trials publication-title: Pharmaceutical Statistics – volume: 57 start-page: 76 issue: 1 year: 2015 end-page: 89 article-title: Adaptive designs for subpopulation analysis optimizing utility functions publication-title: Biometrical Journal – volume: 20 start-page: 130 year: 1989 end-page: 148 article-title: Multistage testing with adaptive designs publication-title: Biometrie und Informatik in Medizin und Biologie – year: 2014 – year: 1998 – volume: 13 start-page: 2455 year: 1994 end-page: 2463 article-title: Internal pilot studies for estimating sample size publication-title: Statistics in Medicine – volume: 41 start-page: 279 year: 1999 end-page: 293 article-title: Multistage adaptive test procedures based on Fisher's product criterion publication-title: Biometrical Journal – volume: 30 start-page: 3267 issue: 28 year: 2011 end-page: 3284 article-title: Adaptive increase in sample size when interim results are promising: A practical guide with examples publication-title: Statistics in Medicine – volume: 41 start-page: 261 year: 1999 end-page: 277 article-title: Inference on multiple endpoints in clinical trials with adaptive interim analyses publication-title: Biometrical Journal – volume: 28 start-page: 1181 year: 2009 end-page: 1217 article-title: Tutorial in biostatistics: Adaptive designs for confirmatory clinical trials publication-title: Statistics in Medicine – volume: 40 start-page: 1079 year: 1984 end-page: 1087 article-title: Procedures for comparing samples with multiple endpoints publication-title: Biometrics – volume: 6 start-page: 227 issue: 3 year: 2007 end-page: 244 article-title: Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset publication-title: Pharmaceutical Statistics – volume: 34 start-page: 591 year: 2000 end-page: 597 article-title: Sequential and multiple testing for dose‐response analysis publication-title: Drug Information Journal – year: 2008 – volume: 23 start-page: 1519 issue: 12 year: 2007 end-page: 1526 article-title: Two‐stage designs applying methods differing in costs publication-title: Bioinformatics – volume: 119 start-page: 597 issue: 4 year: 2009 end-page: 605 article-title: Optimizing trial design sequential, adaptive, and enrichment strategies publication-title: Circulation – volume: 70 start-page: 169 year: 2009 end-page: 190 article-title: Adaptivity in drug discovery and development publication-title: Drug Development Research – volume: 51 start-page: 358 issue: 2 year: 2009 end-page: 374 article-title: Adaptive patient enrichment designs in therapeutic trials publication-title: Biometrical Journal – volume: 65 start-page: 815 issue: 3 year: 2009 end-page: 821 article-title: Flexible designs for genomewide association studies publication-title: Biometrics – volume: 50 start-page: 1029 year: 1994 end-page: 1041 article-title: Evaluation of experiments with adaptive interim analyses publication-title: Biometrics – volume: 13 start-page: 345 issue: 6 year: 2014 end-page: 356 article-title: Adaptive graph‐based multiple testing procedures publication-title: Pharmaceutical Statistics – volume: 60 start-page: 715 year: 2004 end-page: 723 article-title: Optimal conditional error functions for the control of conditional power publication-title: Biometrics – volume: 52 start-page: 798 issue: 6 year: 2010 end-page: 810 article-title: Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials publication-title: Biometrical Journal – volume: 14 start-page: 1039 year: 1995 end-page: 1051 article-title: Planning and revising the sample size for a trial publication-title: Statistics in Medicine – volume: 5 start-page: 293 issue: 4 year: 2013 end-page: 310 article-title: Unblinded adaptive statistical information design based on clinical endpoint or biomarker publication-title: Statistics in Biopharmaceutical Research – volume: 29 start-page: 797 issue: 7‐8 year: 2010 end-page: 807 article-title: The dual test: Safeguarding p‐value combination tests for adaptive designs publication-title: Statistics in Medicine – volume: 18 start-page: 1833 year: 1999 end-page: 1848 article-title: Combining different phases in the development of medical treatments within a single trial publication-title: Statistics in Medicine – volume: 90 start-page: 367 year: 2003 end-page: 378 article-title: On the inefficiency of the adaptive design for monitoring clinical trials publication-title: Biometrika – volume: 19 start-page: 901 year: 2000 end-page: 911 article-title: Re‐calculating the sample size in internal pilot study designs with control of the type I error rate publication-title: Statistics in Medicine – volume: 26 start-page: 2449 issue: 12 year: 2007 end-page: 2464 article-title: Increasing the sample size during clinical trials with t‐distributed test statistics without inflating the type I error rate publication-title: Statistics in Medicine – volume: 45 start-page: 812 issue: 7 year: 2003 end-page: 825 article-title: Sample size reassessment in adaptive clinical trials using a bias corrected estimate publication-title: Biometrical Journal – volume: 27 start-page: 721 year: 1993 end-page: 732 article-title: Internally adaptive designs for parallel group trials publication-title: Drug Information Journal – volume: 51 start-page: 1315 year: 1995 end-page: 1324 article-title: Designed extension of studies based on conditional power publication-title: Biometrics – volume: 30 start-page: 1528 issue: 13 year: 2011 end-page: 1540 article-title: Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis publication-title: Statistics in Medicine – volume: 48 start-page: 732 issue: 4 year: 2006 end-page: 737 article-title: A brief review on software developments for group sequential and adaptive designs publication-title: Biometrical Journal – year: 2007 – volume: 26 start-page: 5002 issue: 27 year: 2007 end-page: 5013 article-title: Flexible two‐stage design with sample size reassessment for survival trials publication-title: Statistics in Medicine – volume: 9 start-page: 277 issue: 4 year: 2010 end-page: 291 article-title: Relative efficacy of drugs: an emerging issue between regulatory agencies and third‐party payers publication-title: Nature Reviews Drug Discovery – year: 2014 article-title: Adaptive survival trials publication-title: arXiv preprint arXiv:1405.1569 – volume: 48 start-page: 473 year: 2014 end-page: 481 article-title: Adaptive design: Results of 2012 survey on perception and use publication-title: Therapeutic Innovation & Regulatory Science – volume: 11 start-page: 53 year: 1992 end-page: 66 article-title: Interim analysis for monitoring clinical trials that do not materially affect the type I error rate publication-title: Statistics in Medicine – volume: 31 start-page: 663 year: 1989 end-page: 676 article-title: Sequential tests of hypotheses in consecutive trials publication-title: Biometrical Journal – volume: 107 start-page: 341 year: 2014 end-page: 348 article-title: Interim design modificcations in time‐to‐event studies publication-title: Journal of the American Statistical Association – start-page: 139 year: 2014 end-page: 155 – volume: 40 start-page: 437 year: 2006 end-page: 444 article-title: Implementing adaptive designs: logistical and operational considerations publication-title: Drug Information Journal – volume: 26 start-page: 5422 issue: 30 year: 2007 end-page: 5433 article-title: Repeated confidence intervals for adaptive group sequential trials publication-title: Statistics in Medicine – volume: 136 start-page: 1956 issue: 6 year: 2006 end-page: 1961 article-title: On the efficiency of adaptive designs for flexible interim decisions in clinical trials publication-title: Journal of Statistical Planning and Inference – volume: 48 start-page: 537 issue: 4 year: 2006 end-page: 555 article-title: Sample size recalculation in internal pilot study designs: a review publication-title: Biometrical Journal – year: 2010 – volume: 32 start-page: 5448 issue: 30 year: 2013 end-page: 5457 article-title: Blinded sample size re‐estimation for recurrent event data with time trends publication-title: Statistics in Medicine – volume: 8 start-page: 146 year: 1987 end-page: 156 article-title: Optimal restricted two‐stage designs publication-title: Controlled Clinical Trials – volume: 17 start-page: 1135 issue: 6 year: 2007 end-page: 1161 article-title: Adaptive seamless designs: selection and prospective testing of hypotheses publication-title: Journal of Biopharmaceutical Statistics – volume: 22 start-page: 689 issue: 5 year: 2003 end-page: 703 article-title: Sequential designs for phase III clinical trials incorporating treatment selection publication-title: Statistics in Medicine – volume: 55 start-page: 1286 issue: 4 year: 1999 end-page: 1290 article-title: Adaptive sample size calculations in group sequential trials publication-title: Biometrics – volume: 97 start-page: 236 year: 2002 end-page: 244 article-title: Recursive combination tests publication-title: Journal of the American Statistical Association – volume: 24 start-page: 168 issue: 1 year: 2014 end-page: 187 article-title: Adaptive designs for confirmatory clinical trials with subgroup selection publication-title: Journal of Biopharmaceutical Statistics – volume: 93 start-page: 1 year: 2006 end-page: 21 article-title: Adaptive and nonadaptive group sequential tests publication-title: Biometrika – volume: 31 start-page: 2041 issue: 19 year: 2012 end-page: 2054 article-title: Adaptive extensions of a two‐stage group sequential procedure for testing primary and secondary endpoints (ii): sample size re‐estimation publication-title: Statistics in Medicine – volume: 24 start-page: 1035 issue: 5 year: 2014 end-page: 1058 article-title: Adaptive sequential testing for multiple comparisons publication-title: Journal of Biopharmaceutical Statistics – volume: 40 start-page: 421 issue: 22 year: 2006 end-page: 484 article-title: White papers publication-title: Drug Information Journal – volume: 21 start-page: 2833 year: 1992 end-page: 2853 article-title: Sample size re‐estimation without unblinding for normally distributed outcomes with unknown variance publication-title: Communications in Statistics ‐ Theory and Methods – volume: 20 start-page: 497 issue: 4 year: 2001 end-page: 513 article-title: Type I error in sample size re‐estimations based on observed treatment difference publication-title: Statistics in Medicine – volume: 17 start-page: 1551 year: 1998 end-page: 1562 article-title: Self‐designing clinical trials publication-title: Statistics in Medicine – volume: 63 start-page: 655 year: 1976 end-page: 660 article-title: On closed testing procedures with special reference to ordered analysis of variance publication-title: Biometrika – volume: 21 start-page: 831 issue: 4 year: 2011 end-page: 845 article-title: Population enrichment designs: case study of a large multinational trial publication-title: Journal of Biopharmaceutical Statistics – year: 2013 – year: 1985 – start-page: 77 year: 2014 end-page: 93 – volume: 33 start-page: 3269 year: 2014 end-page: 3279 article-title: Flexible sequential designs for multi‐arm clinical trials publication-title: Statistics in Medicine – year: 2009 – volume: 47 start-page: 511 issue: 2 year: 1991 end-page: 521 article-title: Procedures for two‐sample comparisons with multiple endpoints controlling the experimentwise error rate publication-title: Biometrics – volume: 9 start-page: 65 year: 1990 end-page: 72 article-title: The role of internal pilot studies in increasing the efficiency of clinical trials publication-title: Statistics in Medicine – volume: 31 start-page: 4309 issue: 30 year: 2012 end-page: 4320 article-title: A conditional error function approach for subgroup selection in adaptive clinical trials publication-title: Statistics in Medicine – volume: 8 start-page: 1 year: 2006 end-page: 16 article-title: Application of adaptive designs ‐ a review publication-title: Biometrical Journal – volume: 23 start-page: 2497 year: 2004 end-page: 2508 article-title: A general statistical principle for changing a design any time during the course of a trial publication-title: Statistics in Medicine – volume: 13 start-page: 317 issue: 5 year: 2014 end-page: 318 article-title: The risks of methodology aversion in drug regulation publication-title: Nature Reviews Drug Discovery – volume: 107 start-page: 824 year: 2012 end-page: 832 article-title: Probabilistic foundation of confirmatory adaptive designs publication-title: Journal of the American Statistical Association – volume: 2443 start-page: 3697 year: 2005 end-page: 3714 article-title: Testing and estimating in flexible group sequential designs with adaptive treatment selection publication-title: Statistics in Medicine – volume: Early View year: 2015 article-title: Adaptive seamless designs with interim treatment selection: a case study in oncology publication-title: Statistics in Medicine – volume: 65 start-page: 539 issue: 2 year: 2009 end-page: 546 article-title: Exact confidence bounds following adaptive group sequential tests publication-title: Biometrics – volume: 43 start-page: 539 year: 2009 end-page: 565 article-title: Good practices for adaptive clinical trials in pharmaceutical product development publication-title: Drug Information Journal – volume: 25 start-page: 917 issue: 6 year: 2006 end-page: 932 article-title: Efficient group sequential designs when there are several effect sizes under consideration publication-title: Statistics in Medicine – volume: 56 start-page: 614 issue: 4 year: 2014 end-page: 630 article-title: Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications publication-title: Biometrical Journal – volume: 50 start-page: 183 year: 1996 end-page: 192 article-title: Statistical packages for group sequential methods publication-title: The American Statistician – volume: 22 start-page: 971 year: 2003 end-page: 993 article-title: Mid‐course sample size modification in clinical trial publication-title: Statistics in Medicine – volume: 29 start-page: 1 issue: 1 year: 2010 end-page: 13 article-title: Selection and bias – two hostile brothers publication-title: Statistics in Medicine – volume: 24 start-page: 1059 issue: 5 year: 2014 end-page: 1072 article-title: Some challenges with statistical inference in adaptive designs publication-title: Journal of Biopharmaceutical Statistics – volume: 30 start-page: 1541 year: 2011 end-page: 1554 article-title: An adaptive confirmatory trial with treatment selection: practical experiences and unbalanced randomization publication-title: Statistics in Medicine – volume: 30 start-page: 171 issue: 2 year: 2009 end-page: 177 article-title: Adaptive trial design: A general methodology for censored time to event data publication-title: Contemporary Clinical Trials – volume: 21 start-page: 802 year: 2011 end-page: 817 article-title: On sample size determination in multi‐armed confirmatory adaptive designs publication-title: Journal of Biopharmaceutical Statistics – volume: 48 start-page: 714 issue: 4 year: 2006 end-page: 729 article-title: Planning and analyzing adaptive group sequential survival trials publication-title: Biometrical Journal – volume: 60 start-page: 910 issue: 4 year: 2004 end-page: 918 article-title: Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials publication-title: Biometrics – volume: 100 start-page: 985 issue: 4 year: 2013 end-page: 996 article-title: Simultaneous confidence intervals that are compatible with closed testing in adaptive designs publication-title: Biometrika – volume: 5 start-page: 61 issue: 1 year: 2006 end-page: 66 article-title: Adaptive designs for pivotal trials: discussion points from the PSI adaptive design expert group publication-title: Pharmaceutical Statistics – volume: 50 start-page: 515 issue: 4 year: 2008 end-page: 527 article-title: Unbiased estimation of selected treatment means in two‐stage trials publication-title: Biometrical Journal – volume: 49 start-page: 94 issue: 1 year: 2007 end-page: 106 article-title: Combining adaptive designs with control of the false discovery rate–a generalized definition for a global p‐value publication-title: Biometrical Journal – volume: 48 start-page: 635 issue: 4 year: 2006 end-page: 643 article-title: Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations publication-title: Biometrical Journal – volume: 17 start-page: 1211 issue: 6 year: 2007 end-page: 1225 article-title: Strategies for including patients recruited during interim analysis of clinical trials publication-title: Journal of Biopharmaceutical Statistics – volume: 56 start-page: 332 issue: 2 year: 2014 end-page: 349 article-title: Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop‐the‐losers trials publication-title: Biometrical Journal – volume: 41 start-page: 689 year: 1999 end-page: 696 article-title: Adaptive two stage designs and the conditional error function publication-title: Biometrical Journal – volume: 9 start-page: 351 year: 2004 end-page: 357 article-title: The advantages and disadvantages of adaptive designs for clinical trials publication-title: Drug Discovery Today – year: 2015 – volume: 46 start-page: 389 year: 2004 end-page: 403 article-title: Conditional rejection probabilities of Student's t‐test and design adaptation publication-title: Biometrical Journal – volume: 23 start-page: 1333 year: 2004 end-page: 1335 article-title: Letter to the Editor: Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections publication-title: Statistics in Medicine – volume: 28 start-page: 739 issue: 5 year: 2009 end-page: 761 article-title: A recycling framework for the construction of Bonferroni‐based multiple tests publication-title: Statistics in Medicine – volume: 65 start-page: 127 year: 2011 end-page: 135 article-title: Group sequential methods and software applications publication-title: The American Statistician – volume: 67 start-page: 1039 issue: 3 year: 2011 end-page: 1046 article-title: An approach to the conditional error rate principle with nuisance parameters publication-title: Biometrics – start-page: 259 year: 2014 end-page: 272 – volume: 72 start-page: 735 issue: 8 year: 2015 end-page: 746 article-title: A randomized controlled trial of oral propranolol in infantile hemangioma publication-title: New England Journal of Medicine – volume: 55 start-page: 341 issue: 3 year: 2013 end-page: 359 article-title: Partition testing in confirmatory adaptive designs with structured objectives publication-title: Biometrical Journal – volume: 35 start-page: 1095 year: 2001 end-page: 1112 article-title: Flexible sample size considerations using information‐based interim monitoring publication-title: Drug Information Journal – volume: 20 start-page: 3861 issue: 24 year: 2001 end-page: 3873 article-title: A comparison of methods for adaptive sample size adjustment publication-title: Statistics in Medicine – volume: 38 start-page: E1644 issue: 6 year: 2001 end-page: E1650 article-title: The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (escami) trial publication-title: Journal of the American College of Cardiology – volume: 47 start-page: 495 year: 2013 end-page: 502 article-title: Views on emerging issues pertaining to data monitoring committees for adaptive trials publication-title: Therapeutic Innovation & Regulatory Science – volume: 18 start-page: 550 year: 1997 end-page: 556 article-title: Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance publication-title: Controlled Clinical Trials – volume: 57 start-page: 886 year: 2001 end-page: 891 article-title: Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches publication-title: Biometrics – volume: 97 start-page: 1034 year: 2002 end-page: 1041 article-title: A unified theory of two‐stage adaptive designs publication-title: Journal of the American Statistical Association – year: 2000 – volume: 22 start-page: 953 issue: 6 year: 2003 end-page: 969 article-title: Issues in designing flexible trials publication-title: Statistics in Medicine – volume: 22 start-page: 111 year: 2001 end-page: 116 article-title: A self‐designing rule for clinical trials with arbitrary variables publication-title: Controlled Clinical Trials – volume: 53 start-page: 894 issue: 6 year: 2011 end-page: 913 article-title: Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests publication-title: Biometrical Journal – volume: 10 start-page: 96 issue: 2 year: 2011 end-page: 104 article-title: Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim publication-title: Pharmaceutical Statistics – volume: 48 start-page: 623 issue: 4 year: 2006 end-page: 634 article-title: Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts publication-title: Biometrical Journal – volume: 31 start-page: 98 issue: 1 year: 2012 end-page: 99 article-title: Comments on Adaptive increase in sample size when interim results are promising: A practical guide with examples by CR Mehta and SJ Pocock publication-title: Statistics in Medicine – volume: 28 start-page: 586 issue: 4 year: 2009 end-page: 604 article-title: A graphical approach to sequentially rejective multiple test procedures publication-title: Statistics in Medicine – volume: 36 start-page: 673 issue: 2 year: 2013 end-page: 681 article-title: Adaptive enrichment with subpopulation selection at interim: Methodologies, applications and design considerations publication-title: Contemporary Clinical Trials – volume: 3 start-page: 279 issue: 3 year: 2014 end-page: 292 article-title: Biomarker adaptive designs in clinical trials publication-title: Translational Cancer Research – year: 2012 – volume: 25 year: 2015 article-title: Designing issues in confirmatory adaptive population enrichment trials publication-title: Journal of Biopharmaceutical Statistics – volume: Accepted year: 2014 article-title: A simple and flexible graphical approach for adaptive group‐sequential clinical trials publication-title: Journal of Biopharmaceutical Statistics – volume: 15 start-page: 383 issue: 1 year: 2014 article-title: Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency publication-title: Trials – volume: 182 start-page: 155 year: 2010 end-page: 162 article-title: Once‐daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium publication-title: American Journal of Respiratory and Critical Care Medicine – volume: 82 start-page: 69 year: 1999 end-page: 81 article-title: Procedures for testing multiple endpoints in clinical trials: An overview publication-title: Journal of Statistical Planning and Inference – volume: 26 start-page: 4925 issue: 27 year: 2007 end-page: 4938 article-title: Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint publication-title: Statistics in Medicine – volume: 40 start-page: 463 year: 2006 end-page: 473 article-title: Adaptive seamless phase II/III designs – background, operational aspects, and examples publication-title: Drug Information Journal – volume: 20 start-page: 2645 year: 2001 end-page: 2660 article-title: Sample size recalculation using conditional power publication-title: Statistics in Medicine – year: 2006 – volume: 33 start-page: 3801 issue: 22 year: 2014 end-page: 3814 article-title: Information‐based sample size re‐estimation in group sequential design for longitudinal trials publication-title: Statistics in Medicine – volume: 20 start-page: 3741 year: 2001 end-page: 3751 article-title: Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections publication-title: Statistics in Medicine – volume: 14 start-page: 36 issue: 4 year: 2009 end-page: 42 article-title: Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs publication-title: Regulatory Affairs Focus – volume: 50 start-page: 767 issue: 5 year: 2008 end-page: 781 article-title: A comparison of methods for adaptive treatment selection publication-title: Biometrical Journal – volume: 23 start-page: 165 year: 2010 end-page: 171 article-title: Integrating indacaterol dose selection in a clinical study in copd using an adaptive seamless design publication-title: Pulmonary Pharmacology & Therapeutics – volume: 15 start-page: 511 year: 2014 end-page: 522 article-title: Continuous infusion of clonidine in ventilated newborns and infants: A randomized controlled trial publication-title: Pediatric Critical Care Medicine – volume: 43 start-page: 821 issue: 7 year: 2001 end-page: 833 article-title: Conditional point estimation in adaptive group sequential test designs publication-title: Biometrical Journal – volume: 16 start-page: 275 year: 2006 end-page: 283 article-title: Adaptive designs in clinical drug development – an executive summary of the PhRMA working group publication-title: Journal of Biopharmaceutical Statistics – volume: 55 start-page: 853 year: 1999 end-page: 857 article-title: Modification of sample size in group sequential clinical trials publication-title: Biometrics – volume: 32 start-page: 3991 issue: 23 year: 2013 end-page: 4005 article-title: Exact inference for adaptive group sequential designs publication-title: Statistics in Medicine – volume: 83 start-page: 1125 issue: 11 year: 2012 end-page: 1132 article-title: Multiple sclerosis and extract of cannabis: results of the MUSEC trial publication-title: Journal of Neurology Neurosurgery and Psychiatry – year: 1999 – volume-title: Modern Adaptive Randomized Clinical Trials: Statistical, Operational, and Regulatory Aspects year: 2015 ident: e_1_2_9_146_1 – ident: e_1_2_9_101_1 doi: 10.1002/sim.3863 – ident: e_1_2_9_32_1 doi: 10.1177/009286150103500407 – ident: e_1_2_9_73_1 doi: 10.1002/sim.3048 – ident: e_1_2_9_115_1 doi: 10.1111/j.1541-0420.2008.01101.x – ident: e_1_2_9_56_1 doi: 10.1002/sim.734 – ident: e_1_2_9_139_1 doi: 10.1164/rccm.200910-1500OC – ident: e_1_2_9_120_1 doi: 10.1111/j.1541-0420.2008.01174.x – ident: e_1_2_9_130_1 doi: 10.1177/216847900604000408 – ident: e_1_2_9_86_1 doi: 10.1002/sim.5377 – ident: e_1_2_9_28_1 doi: 10.1016/0197-2456(87)90039-0 – ident: e_1_2_9_107_1 doi: 10.1002/bimj.200390001 – ident: e_1_2_9_110_1 doi: 10.1002/bimj.200390051 – volume-title: Adaptive Design Theory and Implementation Using SAS and R year: 2008 ident: e_1_2_9_167_1 – ident: e_1_2_9_175_1 doi: 10.1002/(SICI)1097-0258(20000415)19:7<901::AID-SIM405>3.0.CO;2-L – ident: e_1_2_9_16_1 doi: 10.1002/sim.1457 – volume: 40 start-page: 421 issue: 22 year: 2006 ident: e_1_2_9_131_1 article-title: White papers publication-title: Drug Information Journal – ident: e_1_2_9_47_1 doi: 10.1198/016214502388618852 – ident: e_1_2_9_43_1 doi: 10.2307/3109775 – ident: e_1_2_9_123_1 doi: 10.1080/10543406.2014.925911 – ident: e_1_2_9_70_1 doi: 10.1002/sim.3436 – ident: e_1_2_9_119_1 doi: 10.1093/bioinformatics/btm140 – ident: e_1_2_9_4_1 doi: 10.1080/10543400600614742 – ident: e_1_2_9_18_1 doi: 10.1093/biomet/93.1.1 – ident: e_1_2_9_67_1 doi: 10.1002/bimj.200510231 – volume-title: Statistical Monitoring of Clinical Trials. A Unified Approach year: 2006 ident: e_1_2_9_106_1 – ident: e_1_2_9_109_1 doi: 10.1002/sim.2258 – ident: e_1_2_9_148_1 doi: 10.1097/PCC.0000000000000151 – year: 2015 ident: e_1_2_9_103_1 article-title: Adaptive seamless designs with interim treatment selection: a case study in oncology publication-title: Statistics in Medicine doi: 10.1002/sim.6407 – ident: e_1_2_9_129_1 doi: 10.1002/pst.206 – volume-title: Draft Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics year: 2010 ident: e_1_2_9_8_1 – volume: 2443 start-page: 3697 year: 2005 ident: e_1_2_9_63_1 article-title: Testing and estimating in flexible group sequential designs with adaptive treatment selection publication-title: Statistics in Medicine doi: 10.1002/sim.2389 – ident: e_1_2_9_151_1 doi: 10.1016/S0378-3758(99)00032-4 – ident: e_1_2_9_137_1 doi: 10.1016/S0735-1097(01)01608-4 – ident: e_1_2_9_81_1 doi: 10.1080/10543406.2011.554129 – ident: e_1_2_9_177_1 doi: 10.1177/216847900604000409 – volume-title: Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design year: 2007 ident: e_1_2_9_7_1 – ident: e_1_2_9_55_1 doi: 10.1002/sim.1688 – volume: 3 start-page: 279 issue: 3 year: 2014 ident: e_1_2_9_124_1 article-title: Biomarker adaptive designs in clinical trials publication-title: Translational Cancer Research – ident: e_1_2_9_135_1 doi: 10.1002/sim.2957 – ident: e_1_2_9_111_1 doi: 10.1002/1521-4036(200111)43:7<821::AID-BIMJ821>3.0.CO;2-F – ident: e_1_2_9_114_1 doi: 10.1002/sim.3062 – ident: e_1_2_9_49_1 doi: 10.1080/01621459.2012.682540 – ident: e_1_2_9_72_1 doi: 10.1080/10543406.2014.931409 – ident: e_1_2_9_27_1 doi: 10.1002/047005588X – ident: e_1_2_9_68_1 doi: 10.1080/10543406.2011.551336 – ident: e_1_2_9_75_1 doi: 10.1002/pst.472 – ident: e_1_2_9_102_1 doi: 10.1002/sim.4202 – ident: e_1_2_9_39_1 doi: 10.1016/S0197-2456(00)00122-7 – volume: 20 start-page: 130 year: 1989 ident: e_1_2_9_2_1 article-title: Multistage testing with adaptive designs publication-title: Biometrie und Informatik in Medizin und Biologie – ident: e_1_2_9_62_1 doi: 10.1177/009286150003400227 – ident: e_1_2_9_54_1 doi: 10.1002/sim.972 – ident: e_1_2_9_160_1 – ident: e_1_2_9_38_1 doi: 10.1002/(SICI)1097-0258(19980730)17:14<1551::AID-SIM868>3.0.CO;2-E – ident: e_1_2_9_59_1 – ident: e_1_2_9_118_1 doi: 10.1002/sim.3716 – ident: e_1_2_9_61_1 doi: 10.1002/sim.3538 – ident: e_1_2_9_157_1 – ident: e_1_2_9_104_1 doi: 10.1080/10543400701645439 – ident: e_1_2_9_33_1 doi: 10.1002/sim.6192 – ident: e_1_2_9_84_1 doi: 10.1016/S0197-2456(97)00075-5 – ident: e_1_2_9_95_1 doi: 10.1002/sim.2966 – ident: e_1_2_9_14_1 doi: 10.1002/sim.6288 – ident: e_1_2_9_52_1 doi: 10.1111/j.1541-0420.2010.01507.x – ident: e_1_2_9_162_1 doi: 10.32614/CRAN.package.adaptTest – ident: e_1_2_9_24_1 doi: 10.1111/j.0006-341X.2001.00886.x – ident: e_1_2_9_45_1 doi: 10.1002/(SICI)1521-4036(199906)41:3<261::AID-BIMJ261>3.0.CO;2-U – ident: e_1_2_9_57_1 doi: 10.1002/sim.1455 – ident: e_1_2_9_117_1 doi: 10.1093/biomet/ast035 – ident: e_1_2_9_166_1 – ident: e_1_2_9_64_1 doi: 10.1002/bimj.200510232 – start-page: 77 volume-title: Practical Considerations for Adaptive Trial Design and Implementation year: 2014 ident: e_1_2_9_147_1 – ident: e_1_2_9_6_1 doi: 10.1186/1745-6215-15-383 – ident: e_1_2_9_174_1 doi: 10.1002/sim.4780140922 – ident: e_1_2_9_41_1 doi: 10.1002/(SICI)1521-4036(199910)41:6<689::AID-BIMJ689>3.0.CO;2-P – ident: e_1_2_9_136_1 doi: 10.1136/jnnp-2012-302468 – ident: e_1_2_9_12_1 doi: 10.1002/sim.5361 – ident: e_1_2_9_99_1 doi: 10.1080/01621459.2011.644141 – ident: e_1_2_9_171_1 doi: 10.1002/sim.4424 – start-page: 139 volume-title: Practical Considerations for Adaptive Trial Design And Implementation year: 2014 ident: e_1_2_9_156_1 doi: 10.1007/978-1-4939-1100-4_8 – ident: e_1_2_9_19_1 doi: 10.1016/j.jspi.2005.08.014 – ident: e_1_2_9_153_1 doi: 10.2307/2684438 – ident: e_1_2_9_176_1 doi: 10.1016/S1359-6446(04)03023-5 – ident: e_1_2_9_93_1 doi: 10.1002/sim.1136 – ident: e_1_2_9_145_1 doi: 10.1002/sim.4179 – ident: e_1_2_9_10_1 doi: 10.1002/sim.4780132309 – ident: e_1_2_9_122_1 – ident: e_1_2_9_76_1 doi: 10.1002/pst.300 – ident: e_1_2_9_94_1 doi: 10.1002/bimj.200510190 – ident: e_1_2_9_116_1 doi: 10.1002/sim.5847 – ident: e_1_2_9_169_1 doi: 10.1002/sim.3704 – ident: e_1_2_9_78_1 doi: 10.1002/bimj.201300257 – ident: e_1_2_9_85_1 doi: 10.1080/10543400701645405 – ident: e_1_2_9_149_1 doi: 10.2307/2531158 – ident: e_1_2_9_128_1 doi: 10.1038/nrd3079 – start-page: 77 volume-title: Indacaterol ‐ The First Once‐Daily Long‐Acting Beta2 Agonist for COPD year: 2014 ident: e_1_2_9_142_1 doi: 10.1007/978-3-0348-0709-8_5 – ident: e_1_2_9_98_1 doi: 10.1002/sim.6272 – ident: e_1_2_9_87_1 doi: 10.1002/sim.3495 – year: 2014 ident: e_1_2_9_100_1 article-title: Adaptive survival trials publication-title: arXiv preprint arXiv:1405.1569 – ident: e_1_2_9_48_1 doi: 10.1016/j.jspi.2005.08.015 – ident: e_1_2_9_60_1 doi: 10.1093/biomet/63.3.655 – ident: e_1_2_9_163_1 – ident: e_1_2_9_26_1 doi: 10.1201/EBK1439825488 – start-page: 77 volume-title: Practical Considerations for Adaptive Trial Design and Implementation year: 2014 ident: e_1_2_9_143_1 – ident: e_1_2_9_89_1 doi: 10.1002/sim.3513 – ident: e_1_2_9_71_1 doi: 10.1002/sim.6183 – ident: e_1_2_9_178_1 doi: 10.1177/009286150904300503 – ident: e_1_2_9_90_1 doi: 10.1002/bimj.201200218 – ident: e_1_2_9_25_1 doi: 10.1002/sim.1852 – ident: e_1_2_9_58_1 doi: 10.1002/sim.2180 – ident: e_1_2_9_83_1 doi: 10.1080/10543406.2013.857238 – ident: e_1_2_9_23_1 doi: 10.2307/2533262 – ident: e_1_2_9_15_1 doi: 10.1093/biomet/90.2.367 – ident: e_1_2_9_168_1 doi: 10.1002/pst.302 – ident: e_1_2_9_74_1 doi: 10.1002/sim.3559 – ident: e_1_2_9_180_1 doi: 10.1038/nrd4319 – ident: e_1_2_9_108_1 doi: 10.1111/j.0006-341X.2004.00246.x – ident: e_1_2_9_82_1 doi: 10.1002/sim.5541 – volume: 14 start-page: 36 issue: 4 year: 2009 ident: e_1_2_9_132_1 article-title: Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs publication-title: Regulatory Affairs Focus – ident: e_1_2_9_20_1 doi: 10.1111/j.1541-0420.2006.00626.x – ident: e_1_2_9_22_1 doi: 10.1111/j.0006-341X.1999.00853.x – ident: e_1_2_9_121_1 doi: 10.1002/bimj.200510311 – ident: e_1_2_9_126_1 doi: 10.1080/19466315.2013.791639 – ident: e_1_2_9_125_1 doi: 10.1016/j.cct.2013.09.008 – ident: e_1_2_9_53_1 doi: 10.1002/sim.531 – ident: e_1_2_9_179_1 doi: 10.1177/2168479013486996 – volume-title: Guideline on Clinical Trials in Small Populations (chmp/ewp/83561/2005) year: 2006 ident: e_1_2_9_152_1 – ident: e_1_2_9_159_1 – ident: e_1_2_9_164_1 – ident: e_1_2_9_30_1 doi: 10.1002/sim.1362 – ident: e_1_2_9_138_1 doi: 10.1177/2168479014522468 – ident: e_1_2_9_134_1 doi: 10.1002/ddr.20285 – start-page: 259 volume-title: Practical Considerations for Adaptive Trial Design and Implementation year: 2014 ident: e_1_2_9_141_1 doi: 10.1007/978-1-4939-1100-4_14 – ident: e_1_2_9_92_1 doi: 10.1002/pst.1640 – ident: e_1_2_9_17_1 doi: 10.1002/sim.2251 – ident: e_1_2_9_11_1 doi: 10.1002/bimj.200510238 – ident: e_1_2_9_161_1 – ident: e_1_2_9_51_1 doi: 10.1002/sim.2725 – ident: e_1_2_9_173_1 doi: 10.1080/03610929208830947 – ident: e_1_2_9_37_1 doi: 10.1198/016214502753479374 – volume-title: Statistical Methods for Meta‐Analysis year: 1985 ident: e_1_2_9_35_1 – ident: e_1_2_9_65_1 doi: 10.1080/10543400701645215 – ident: e_1_2_9_172_1 doi: 10.1002/sim.4780110107 – ident: e_1_2_9_154_1 doi: 10.1002/bimj.200510233 – ident: e_1_2_9_13_1 doi: 10.1002/sim.5977 – ident: e_1_2_9_34_1 doi: 10.1002/pst.413 – ident: e_1_2_9_3_1 doi: 10.2307/2533441 – ident: e_1_2_9_77_1 doi: 10.1002/bimj.200900003 – ident: e_1_2_9_170_1 doi: 10.1002/sim.4102 – ident: e_1_2_9_5_1 doi: 10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>3.0.CO;2-3 – volume: 31 start-page: 663 year: 1989 ident: e_1_2_9_36_1 article-title: Sequential tests of hypotheses in consecutive trials publication-title: Biometrical Journal doi: 10.1002/bimj.4710310600 – ident: e_1_2_9_46_1 doi: 10.1002/1521-4036(200109)43:5<581::AID-BIMJ581>3.0.CO;2-J – ident: e_1_2_9_127_1 doi: 10.1002/bimj.200900207 – ident: e_1_2_9_113_1 doi: 10.1002/bimj.201200245 – ident: e_1_2_9_158_1 – ident: e_1_2_9_144_1 doi: 10.1056/NEJMoa1404710 – ident: e_1_2_9_140_1 doi: 10.1016/j.pupt.2010.01.003 – ident: e_1_2_9_21_1 doi: 10.1111/j.0006-341X.1999.01286.x – ident: e_1_2_9_29_1 doi: 10.1177/009286159302700314 – ident: e_1_2_9_155_1 doi: 10.1198/tast.2011.10213 – ident: e_1_2_9_66_1 doi: 10.1177/216847900604000412 – ident: e_1_2_9_69_1 doi: 10.1002/bimj.200710453 – ident: e_1_2_9_80_1 doi: 10.1161/CIRCULATIONAHA.108.809707 – ident: e_1_2_9_44_1 doi: 10.1111/j.0006-341X.2004.00221.x – ident: e_1_2_9_97_1 doi: 10.1002/sim.1759 – ident: e_1_2_9_96_1 doi: 10.1016/j.cct.2008.12.002 – ident: e_1_2_9_79_1 doi: 10.1080/10543406.2014.920869 – ident: e_1_2_9_88_1 doi: 10.1002/bimj.201000239 – volume-title: Group Sequential Methods with Applications to Clinical Trials year: 2000 ident: e_1_2_9_105_1 – ident: e_1_2_9_165_1 – ident: e_1_2_9_40_1 doi: 10.1002/(SICI)1521-4036(199906)41:3<279::AID-BIMJ279>3.0.CO;2-V – volume: 8 start-page: 1 year: 2006 ident: e_1_2_9_133_1 article-title: Application of adaptive designs ‐ a review publication-title: Biometrical Journal – ident: e_1_2_9_150_1 doi: 10.2307/2532142 – year: 2014 ident: e_1_2_9_91_1 article-title: A simple and flexible graphical approach for adaptive group‐sequential clinical trials publication-title: Journal of Biopharmaceutical Statistics – volume-title: Statistische Testverfahren für gruppensequentielle und adaptive Pläne in klinischen Studien. Theoretische Konzepte und deren praktische Umsetzung mit SAS year: 1999 ident: e_1_2_9_42_1 – ident: e_1_2_9_112_1 doi: 10.1002/bimj.200810442 – ident: e_1_2_9_31_1 doi: 10.1002/bimj.201300153 – ident: e_1_2_9_50_1 doi: 10.1002/bimj.200410042 – ident: e_1_2_9_9_1 doi: 10.1002/sim.4780090113 – reference: 26757952 - Stat Med. 2016 Feb 10;35(3):348-9 – reference: 26757956 - Stat Med. 2016 Feb 10;35(3):364-7 – reference: 26757953 - Stat Med. 2016 Feb 10;35(3):350-8 – reference: 26757954 - Stat Med. 2016 Feb 10;35(3):359-61 – reference: 26757955 - Stat Med. 2016 Feb 10;35(3):362-3 |
SSID | ssj0011527 |
Score | 2.5527565 |
Snippet | ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in... 'Multistage testing with adaptive designs' was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in... ‘Multistage testing with adaptive designs’ was the title of an article by Peter Bauer that appeared 1989 in the German journal Biometrie und Informatik in... |
SourceID | pubmedcentral proquest pubmed crossref wiley istex |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 325 |
SubjectTerms | adaptive design Biometrics Biometry - methods Biostatistics clinical trials Clinical Trials as Topic - methods Clinical Trials as Topic - statistics & numerical data Data Interpretation, Statistical Endpoint Determination - methods Endpoint Determination - statistics & numerical data group sequential designs Humans Meta-Analysis as Topic Research Design Sample Size Software Software Design |
Title | Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls |
URI | https://api.istex.fr/ark:/67375/WNG-TJ0Z7R0Z-6/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fsim.6472 https://www.ncbi.nlm.nih.gov/pubmed/25778935 https://www.proquest.com/docview/1759164194 https://www.proquest.com/docview/1760903988 https://pubmed.ncbi.nlm.nih.gov/PMC6680191 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkVAlxGN5dKFURkJwyjZxHGfDDSFKqbRV1S6iKofIdmyx6jZZbXYFy4mfwG_klzCTFywUCXHKwWM5tmfG39jjzwBPI-tLJ63ytI2sJ2yiPa1C7pmhwdXZ4QrI6YLz6FDuvxMHp9Fpk1VJd2Fqfohuw40so_LXZOBKl7s_SUPLycWAuM_R_VKqFuGh4445Kmhfa6UTShkHUcs76_PdtuLaSnSNBvXzZTDzz2zJX1FstQzt3YIPbQfq7JPzwXKhB-bLb9yO_9fD23CzQafsZa1Od-CKzXtwfdScv_fgRr3Lx-rLSz3YJKxaUz3fhaPxJ_z31fev3xy6ULZCGypZ4RhG3G5CyLiYr5jK1Iw8LMuq1JHyBStmFAIs84ralak8Y7PJwqnptLwHJ3uvx6_2vebBBs8gUELPygOtEmFDi6GvVU5xxTOTCYxpNMIQ3wQu1kFsXBZrwwPp_MTEZigsxqBGhfdhIy9yuwUsE-j2QoyknE0Et1JZh7omkjC0kmOtPjxvpy41DZc5PakxTWsWZp7i2KU0dn140knOav6OS2SeVbPfCaj5OeW7xVH6_vBNOj7wz-Jj_yyVfdhu1SNtTL1MEX8hxBZBIrCtrhiNlE5eVG6LJclI2g9LhsM-PKi1qWsMfWaMoDHqQ7ymZ50AEYCvl-STjxURuJSIL5IA_79So792MD15O6Lvw38VfASbCAyr7PTA34aNxXxpHyP4WugduMrF0U5lbD8AF_wwAQ |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwED-NTYJJiD8FRmCAkRA8pUucxGngCSFGN9YKbUWbJiTLcWxRrUuqphWUJz4Cn5FPwtn5A4UhIZ7y4LMc23fn39nnnwGeRMpjminhpipSbqiS1E1FQF3Zk7g6a1wBqbngPBiy_vtw_yQ6WYMXzV2Yih-i3XAzlmH9tTFwsyG985M1tByfdw35-SXYMA9623jqsOWO8pv3Ws0ZJYv9qGGe9ehOU3NlLdoww_r5IqD5Z77krzjWLkS71-FD04Uq_-Ssu5inXfnlN3bH_-zjDbhWA1TystKom7Cm8g5cHtRH8B24Wm30ker-Ugc2DVyt2J5vwbvRJ_z55fev3zR6UbJEMypJoQkG3XpswHExWxKRialxsiSz2SPlc1JMTRSwyC27KxF5RqbjuRaTSXkbjnZfj1713frNBlciVkLnSv1UJKEKFEa_SmhBBc1kFmJYkyIS8aSv49SPpc7iVFKfaS-RseyFCsNQKYI7sJ4XuboLJAvR8wUYTGmVhFQxoTSqW5gEgWIUaznwrJk7Lms6c_OqxoRXRMyU49hxM3YOPG4lpxWFxwUyT-30twJidmZS3uKIHw_f8NG-dxofeqecObDd6Aevrb3kCMEQZYd-EmJbbTHaqTl8EbkqFkaGmS2xpNdzYKtSp7YxdJsx4sbIgXhF0VoBwwG-WpKPP1oucMYQYiQ-_r_Vo792kB_tDcz33r8KPoIr_dHggB_sDd_eh03EiTZZ3fe2YX0-W6gHiMXm6UNrcz8AvHYzRQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BK1WVKh7LK1DASAhO2ebhOAk3RFnawq6qdhFVe7Acx1ZXXZJosytYTvwEfiO_hHFesFAkxCkHj-XYnhl_Y48_AzwNlMM0U8JOVKBsquLEToTv2TKSuDprXAE9c8F5OGJ77-nBSXDSZFWauzA1P0S34WYso_LXxsCLVO_8JA0tJx_7hvv8KqxT5kRGo3ePOuoot32u1RxRstANWuJZx9tpa64sRetmVD9fhjP_TJf8FcZW69DgOpy1PajTTy76i3nSl19-I3f8vy7egGsNPCUva326CVdU1oONYXMA34OtepuP1LeXerBpwGrN9XwLDsef8N-X379-0-hDyRKNqCS5Jhhy64mBxvlsSUQqCuNiSVrljpQvSF6YGGCRVdyuRGQpKSZzLabT8jYcD16PX-3ZzYsNtkSkhK7VcxMRU-UrjH2V0MITXipTikFNgjjEka4OEzeUOg0T6blMO7EMZUQVBqFS-HdgLcszdQ9IStHv-RhKaRVTTzGhNCobjX1fMQ9rWfC8nTouGzJz86bGlNc0zB7HseNm7Cx40kkWNYHHJTLPqtnvBMTswiS8hQH_MHrDxwfOaXjknHJmwXarHryx9ZIjAEOMTd2YYltdMVqpOXoRmcoXRoaZDbE4iiy4W2tT1xg6zRBRY2BBuKJnnYBhAF8tySbnFRM4YwgwYhf_v1Kjv3aQH-8Pzff-vwo-ho3D3QF_tz96-wA2ESRWmequsw1r89lCPUQgNk8eVRb3AypYMf0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Twenty%E2%80%90five+years+of+confirmatory+adaptive+designs%3A+opportunities+and+pitfalls&rft.jtitle=Statistics+in+medicine&rft.au=Bauer%2C+Peter&rft.au=Bretz%2C+Frank&rft.au=Dragalin%2C+Vladimir&rft.au=K%C3%B6nig%2C+Franz&rft.date=2016-02-10&rft.issn=0277-6715&rft.eissn=1097-0258&rft.volume=35&rft.issue=3&rft.spage=325&rft.epage=347&rft_id=info:doi/10.1002%2Fsim.6472&rft.externalDBID=10.1002%252Fsim.6472&rft.externalDocID=SIM6472 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0277-6715&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0277-6715&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0277-6715&client=summon |